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Abstract 
 Worldwide, many fungal species have been used for their medicinal properties by 
various cultures for centuries. Major challenges with cancer chemotherapy, which 
includes toxicity, non-specificity and several adverse effects have motivated 
researchers to search for novel anti-cancer compounds from natural sources. Several 
studies have identified various anti-cancer compounds from mushrooms in many parts 
of the world, but mushrooms occurring in British Columbia remain unstudied for their 
anti-cancer activities. In this thesis, five mushroom species were collected, extracted, 
and assessed for anti-proliferative and immuno-stimulatory activities. Eleven extracts 
from these species showed anti-proliferative or immuno-stimulatory activity or both. 
Sodium hydroxide extract from Paxillus obscurisporus exhibited potent anti-proliferative 
activity and was further purified using size-exclusion and anion-exchange 
chromatography. Analysis of the relatively pure anti-proliferative fractions suggests the 
presence of protein and glycoprotein moieties. Further purification and characterisation 
is needed before these compounds can be tested for biomedical purposes in the future.   
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Chapter 1 
Introduction 
 Worldwide, cancer is one of the major public health problems and the leading 
cause of deaths in developed countries, and second largest cause of death in the 
developing countries (Coughlin & Ekwueme, 2009; Jemal et al., 1999).Treatment 
options for cancer include radiotherapy, immunotherapy, and chemotherapy. But, 
limited efficacy, unspecified tissue targets, and increasing toxicity associated with 
cancer chemotherapy are some of many problems which makes cancer treatment very 
complicated (Golub et al., 1999). The major toxicity issues involved in cancer 
chemotherapy includes cardiovascular complications [e.g. cardiotoxicity, heart failure, 
myocardial ischemia (Yeh et al., 2004), neurological complications (e.g. central nervous 
system toxicity, peripheral nervous system toxicity, encephalopathy etc.) (Hildebrand, 
2006), and renal complications (e.g. nephrotoxicity, renal failure, renal impairment) 
(Ries & Klastersky, 1986)].The ever-increasing complications and toxicity involved in 
cancer chemotherapy suggests a continuing necessity to find new medicinal 
compounds with lower toxicity and better efficacy.    
1.1  Natural products as source of medicinal compounds 
 Humans have relied on nature for sourcing of various medicines to treat a wide 
spectrum of diseases throughout the ages. While leading pharmaceutical discovery over 
the past century, natural products have been a constant source of chemical diversity for 
various pharmaceutical precursors (Mishra & Tiwari, 2011). It is widely accepted that 
about 80% of drugs were based on natural compounds before the advent of synthetic 
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pharmaceuticals and high throughput screening of combinatorial libraries (Sneader, 
2006). However, it is worth noticing that almost 50% of the drugs approved from 1994-
2009 were still based on natural products (Butler, 2008). These natural products cover a 
range of therapeutic medications including anti-cancer, anti-infectious, and anti-diabetic 
agents.  It is estimated that about 60% of the anti-cancer agents used today are directly 
or indirectly derived from natural sources including plants, marine organisms, fungi, and 
microorganisms (Cragg & Newman, 2005).  
 Because of increasing interest of the pharmaceutical industry in screening of 
small molecule libraries obtained from combinatorial chemistry techniques, there has 
been a significant drop in interest to pursue natural products as sources of medicinal 
agents. There are many disadvantages of natural product chemistry. There are 
difficulties in access and supply of the natural products from various natural sources. 
The complexity in natural product chemistry leads to inability to maintain high-quality 
natural product libraries, as it demands highly skilled individuals. The process of the 
screening of natural product is slow because of the complex nature of the crude extracts 
obtained from the natural sources. Duration of screening of natural products is slower 
compared to screening of compounds obtained from combinatorial chemistry. Structural 
complexity and large molecular size of natural products make their modification 
challenging. And finally there are concerns about intellectual property rights of natural 
products (Lam, 2007; Singh & Barrett, 2006).The problems mentioned in this paragraph 
that are associated with natural product drug discovery turned the focus of the 
pharmaceutical industry towards discovery of novel drugs through high throughput 
screening of small molecular libraries generated by combinatorial chemistry.  
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Nevertheless, disappointing results were experienced by the pharmaceutical 
industry from screening of these libraries obtained from the combinatorial chemistry 
(Newman & Cragg, 2012). It was believed that the lack of chemical diversity from those 
libraries led to disappointing drug discovery results (Macarron et al., 2011; Sukuru et al., 
2009). 
 Recent advances in functional assays, phenotypic screening processes, and 
genomic/metabolomic approaches have led to a fusion of traditional and contemporary 
methods to assess natural product bio-activity and this is contributing to renewed 
interest in natural products drug discovery (Harvey et al., 2015).   
1.2  Medicinal Mushrooms  
Mushrooms have been known for their medicinal and culinary use for thousands 
of years (Chen et al., 2013). Mushrooms were consumed by people of eastern Asia for 
their culinary and medicinal properties since ancient times. Egyptian hieroglyphics, 
which are about 4500-year-old, depict mushrooms as gifts from gods (Halpern, 2006; 
Sullivan et al., 2006), indicating the medicinal significance of the mushrooms in that era. 
Many ancient civilizations worldwide have discovered that hot water extract of many 
mushroom species have surprising medicinal effects. In China and Japan particularly, 
hot water extracts of selected mushroom species are used in several treatments in 
traditional medicine (Dias et al., 2004).  In the recent past, mushrooms were considered 
as a miniature pharmaceutical manufacturers, synthesizing pharmacologically-active, 
biochemical compounds (Patel & Goyal, 2012). In countries like Japan, China, the 
U.S.A., and Russia there are several bio-active natural molecules extracted from the 
fruiting bodies of mushrooms such as Lentinus edodes, Ganoderma lucidum, 
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Schizophyllum commune, Trametes versicolor, Inonotus obliquus, and Flamulina 
velutipes. These natural molecules have been shown to strengthen the immune system, 
and hence used in various disease treatment (Wasser & Weis, 1999). 
The use of Ganoderma and related species as a medicinal agent in traditional 
medicine dates back thousands of years (Zhao et al., 1994) and is a well-studied 
mushroom across the globe. It is commonly referred to as Lingzhi in China and its 
pharmacological actions includes immuno-modulation through an effect on dendritic 
cells (Chan et al., 2007). The other medicinal activities of Ganoderma spp. includes 
anti-inflammatory, anti-cancer (Kim et al., 2007), anti-diabetic, anti-oxidative (Sun et al., 
2004), anti-aging (Bisen et. al., 2010), and radical scavenging (Baskar et al., 2008). 
Dried powder of G. lucidum is used in east Asian countries as a preventative household 
medicine against various diseases including prostate and breast cancers (Sliva et al., 
2003).  
S. commune is another medicinal mushroom credited with numerous medicinal 
activities (Mirfat, 2008) consisting of anti-tumor (Han et al., 2005), and anti-oxidant 
properties (Yim et al., 2013). Also, S. commune has been found to exhibit anti-
proliferative activity on breast and hepatic cancer cell lines (Mansour et al., 2012). For 
its numerous nutritional benefits, the people of southeast Asia consumed S. commune 
as nutritional food (Han et al., 2005). 
T. versicolor is a well-studied and well-documented mushroom that has 
numerous health benefits: it has a variety of medicinal effects including antiviral, anti-
tumor, and immuno-modulatory (Chu et al., 2002). It was discovered that T. versicolor 
biosynthesizes polysaccharides and proteins that are responsible for pharmacological 
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actions and health benefits (Li et al., 2011). Most of the mushroom compounds seem to 
exert their effects through immuno-modulation, and so does polysaccharide-krestin 
(PSK). PSK was isolated from T. versicolor and had been used as an assistive anti-
tumor medicine in Asia since the 1970’s (Fisher, 2002). Studies show that PSK exerts 
its immuno-modulatory effect by binding to TRL4 receptors that leads to induction of 
TNF-alpha and IL6 inflammatory cytokines (Price et al., 2010).  
I. obliquus is one of the most popular and effective medicinal mushrooms. It has 
been used for nutritive and medicinal benefits in Russia and Europe for more than four 
centuries (Zheng et al., 2009). Commonly known as “Chaga”, it consists of many 
metabolites that are biologically active, having hypoglycemic (Sun et al., 2008), hepato-
protective (Wasser, 2010), anti-fungal (Kim et al., 2011), and anti-tumor activities 
(Kahlos & Tikka, 1994; Taji et al., 2008). Studies show that Chaga produces various 
phenolic compounds like hispidin analogues and melanins, that are considered to 
actively inhibit replication of HIV-1, H1N1, and H3N2 influenza virus (Ichimura et al., 
1998; Kukulyanskaya et al., 2002). Known for it’s various biological activities, Chaga is 
considered one of the most significant medicinal mushrooms.  
A lot of mushrooms are proven to have medicinal properties. These medicinal 
mushrooms includes different species from genera Phellinus, Pleurotus, Agaricus, 
Ganoderma, Clitocybe, Antrodia, Trametes, Coprinus (Dotan et al., 2011), Grifola 
(Harada et al., 2003) Cordyceps, Xerocomus, Calvatia, Schizophyllum, Flammulina, 
Suillus, Inonotus, Inocybe, Funalia, Lactarius, Albatrellus, Russula, and Fomes (Patel & 
Goyal, 2012). Only a small group of mushroom species are studied for their medicinal 
properties, and many mushroom species remain unstudied for their medicinal activities.  
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Hawksworth (2001) established that approximately 1.5 million species of fungi 
exist, out of which approximately 85,000 are recognized and documented. Of those 
85,000 recognized and documented species, 20,000 identified species are macro-fungi, 
of which about 5000 mushrooms are edible (Mahajna et al., 2009). There are about 20-
25 genera of mushrooms studied for their medicinal activities, leaving a plethora of 
mushroom species that remain unexplored for their biological activity. These unexplored 
species can be biologically active and used in treating lethal diseases such as cancer.   
1.3  Medicinal Compounds from Mushrooms and their Biological Activity 
1.3.1 Active Anti-Tumor Compounds 
Mushrooms are known for their nutritional and medicinal values, and have been 
used clinically for the treatment of various diseases like cancer, diabetes, bacterial 
infections, viral infections, and ulcers. Polysaccharides and β-glucans are some of the 
biologically active compounds from mushrooms (Kim et al., 2013). Krestin from T. 
versicolor, Mesima from P. linteus, Lentinan from L. edodes, and Schizophyllan from S. 
commune (Li et al., 2004; Yamasaki et al., 2009; Zhou et al., 2009) are some of the 
most well-known mushroom polysaccharides. The bio-active medicinal compounds are 
classified into two different classes. Low Molecular Weight (LMW) bio-active 
compounds (example: quinones, cerebrosides, isoflavones, catechols, amine, 
triacylglycerols, sesquiterpenes, steroids, organic germanium, and selenium) and High 
Molecular Weight (HMW) bio-active compounds (example: proteoglycans, hetero-
glucans, homo-glucans, glucans, glycoproteins, proteins, glycol-peptides, and lectins) 
(Ferreira et al., 2010)  
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Studies reveal that Low Molecular Weight (LMW) compounds target processes 
like angiogenesis, cell cycle growth, apoptosis, metastasis, and signal transduction 
cascades to bring out biological activities, whereas High Molecular Weight (HMW) 
compounds like polysaccharides and polysaccharide-protein complexes target innate 
and cell-mediated immune responses (Zaidman et al., 2005). 
1.3.2  Active Anti-Microbial Compounds 
Several compounds isolated from mushrooms are reported to have anti-microbial 
activity such as antifungal, antibacterial and antiviral. Adustin, Aleurodiscal, 
Anisaldhyde, Clavilactones, Fimicolons, Fomecins, Cheimonophyllon A and E, 
Strobilurin E, Cyathiformine A, and Favolon are examples of anti-fungal compounds that 
have been isolated from mushrooms; Armillarin, Basidalin, Crinipellins, and Frustulosin 
are examples of compounds obtained from mushrooms that possess anti-bacterial 
activity; Clitocine, Ganoderan, Collybial, Filoboletic acid, Lentinan, and Nebularine are 
examples of anti-viral compounds obtained from mushrooms (Zhong, 2004). Table 1.1 
summarizes some of the currently known anti-microbial compounds isolated from 
mushrooms. 
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Table 1.1: Mushroom bio-active compounds exhibiting various antimicrobial effects.  
Mushrooms Bio-active 
Compounds 
Bio-activity Reference 
Cheimonophylum 
candissimum 
Cheimonophyllon A&E Antibacterial, Weak 
antifungal. 
Stadler et al., 
1994. 
Clitocybe 
cyathiformis 
Cyathiformine A Antibacterial and 
Antifungal. 
Arnone et al., 
1993. 
Clitocybe diatreta Diatretol Antibacterial  Arnone et al., 
1996. 
Coprinus 
atramentarius 
Illudin C2, Illudin C3 Antimicrobial Lee et al., 
1996. 
Crepidotus 
fulvotomentosus 
Strobilurin E Antifungal Weber et al., 
1989. 
Favolaschia 
pustulosa 
9-Methoxystrobilurin L Antifungal and 
Antibacterial 
Wood et al., 
1996. 
Favolaschia sp. Favolon Antifungal Anke et al., 
1995. 
Flagelloscypha pilatii Pilatin Antibiotic Heim et al., 
1988. 
Ganoderma lucidum Ganoderan Antiviral Wasser, 2005. 
Lentinus edodes Lentinan Antiviral Mizuno, 2000. 
Mniopetalum sp. Mniopetals Antimicrobial Kuschel et al., 
1994. 
Mycena sp. Strobilurin M, 
Tertachloropyrocatechol 
Antifungal, 
Cytostatic. 
Antifungal, 
Antibacterial. 
Daferner et al., 
1998. 
Omphalotus illudens Illudinic acid Antibacterial Dufresne et 
al., 1997. 
Oudemansiella 
radicata 
Oudemansin X Antifungal Anke et al., 
1990.  
Table adopted from (Rai et al., 2005; Zhong 2004) 
1.3.3 Bio-active Hypoglycemic Compounds 
 Most of the fungal polysaccharides are non-digestible in the human 
intestinal track, making them a good source of fiber that could reduce glucose release 
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and lessen accumulation of cholesterol in the blood. Fungal glucans from L. edodes, G. 
ludidum, S. commune, Sclerotium rolfsii, Grifolia frondosa, Agaricus blazei, Cordiceps 
miltaris, Pleurotus ostreatus, and Saccharomyces cerevisiae have been proven to 
reduce the blood cholesterol levels and mitigate hypoglycemic/hypolipidemic effects, in 
human and animal studies (Biliaderis and Izydorczyk 2007; Giavasis, 2013; Wasser, 
2002; Zhong, 2004; Waszkiewicz-Robak, 2013). Lentinan isolated from the mushroom 
L. edodes, is used as an effective hypocholesterolemic agent for humans; it breaks 
down blood lipoproteins, both Low Density Lipoproteins (LDL) and High Density 
Lipoproteins (HDL) (Rana, 2005). 
1.4  Medicinal Compounds from Mushrooms in Clinical Use 
Clinical trials for many medicinal compounds from mushrooms have been 
conducted. Most of these medicinal compounds that have undergone clinical trials were 
found to be beneficial to cancer patients. Polysaccharides extracted from G. frondosa, 
Agaricus brasiliensis, L. edodes, G. lucidum, T. versicolor, and Cordyceps sinensis are 
used to produce tablets and another dosage forms for their tumoricidal and immuno-
modulatory activity. G. lucidum is prescribed in various dosage forms like injectable, 
capsule, tincture, tea, and soup (Rai et al., 2005).  Table 2 summarizes some of the 
medicinal mushroom compounds that are currently in clinical use. 
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Table 1.2: Medicinal mushroom compounds currently in clinical use for cancer and 
assistive therapy 
Mushroom Disease Dose Reference 
Oral Administration 
Trametes versicolor 
(PSK) 
Lung Cancer 3 Capsules 
(350mg- Thrice a 
day) 
Tsang et al., 
2003 
Trametes versicolor 
(PSP) 
Immunosuppression 2gm/kg/day Qian et al., 
1997. 
Trametes versicolor 
(PSP) 
HIV-1 6.25mg/ml Collins and 
Ng, 1997. 
Ganoderma lucidum 
(Ganopoly) 
Advanced cancer 600mg, thrice a 
day. 
Gao et al., 
2002. 
Grifola frondosa (D-
Fraction) 
Various cancer 100mg/day for 34 
months. 
Kodama et al., 
2002. 
Intraperitoneal Administration 
Sparassis crispa Cancer  250-1000 
microgram/mouse 
Harada et al., 
2002. 
Phellinus linteus Cancer 100mg/kg of the 
acidic 
polysaccharide. 
Kim et al., 
2003. 
Agaricus brasiliensis (F3-
2-b and 5FU) 
Meth A Tumor Cell 100mg/kg/day for 
30 days. 
Itoh et al., 
1997. 
PSP- Polysaccharide Peptide, 
PSK- Polysaccharide Krestin, 
Ganopoly- Crude polysaccharide fraction 
 Table adaped from Rai et al (2005) 
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1.5  British Columbia Wild Mushrooms 
British Columbia (BC) is home to a biodiverse fungal community. Because of this 
biodiversity in mushrooms, we hypothesized that the mushrooms found in BC may have 
compounds with medicinal properties. To date, there have been no studies reported on 
the screening of BC wild mushrooms for biological activities that are relevant to cancer. 
A table generated by Dr. Chow Lee and Dr. Keith Egger (unpublished data in Table 3) 
differentiates the various selected mushrooms found in BC. Group A includes the 
mushrooms that are reported to have compounds with biological activities. Group B 
consists of mushrooms that are related to those in group A, but have not been studied 
for biological activity. Group C is comprised of mushrooms that are not related to those 
in group A, and have not been studied for their biological activity.   
 Based on Table 1.3, mushrooms species in BC like Agaricus bisporus, Pleurotus 
sajor-caju/pulmonarius, P. ostreatus, and Sarcodon scabrosus are reported to have 
biologically active compounds, confirming the presence of medicinal mushrooms in the 
province. Looking at group B and C, it is evident that there are many mushrooms 
species that are yet to be studied for their potential biological activity. This suggests the 
high possibility of discovering novel bio-active compounds.  
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Table 1.3: Selected list of wild mushrooms present in BC characterized depending upon 
their medicinal potential. 
Groups  Mushroom species  Biologically active 
compound(s)  
A  Agaricus bisporus  
Pleurotus sajor-caju/pulmonarius  
Pleurotus ostreatus  
Sarcodon scabrosus  
Inonotus obliquus  
Ganoderma lucidum  
Trametes (Coriolus) versicolor  
Albatrellus confluens  
Hericium erinaceus 
Amanita muscaria 
Phellinus nigricans 
Phellinus igniarius  
  
Linoleic acid, linolenic acid.  
β-glucans.  
α-glucans.  
Diterpene.  
Polyphenols.  
Polysaccharides, triterpene.  
Polysaccharide—peptide or 
protein.  
Grifolin.  
β-glucans. 
Endo-polysaccharides  
Endo-polysaccharides 
B  Agaricus albolutescens; subrufescens; 
arvensis; augustus; diminitivus; subrutilescens; 
nivescens; inapertus; excellens; emotus.  
Presently unknown  
C  Pleurotus dryinus; populinus.  
Sarcodon calvatus; fuscoindicus; imbricatus; 
indurescens; tereosarcinon; 
underwodii;atrovinidis; leucopus; rimosus; 
subincamatus; versipellis.  
Inonotus cuticularis; glomeratus; tomentosus.  
Phellinus conchatus; gilvus; prunicola; 
repandus; tremulae; everharti; occidentalis; 
pomaceus.  
Antrodia albida; albobrunnea; carbonica; 
heteromorpha; malicola; serialis; sinuosa; 
sitchensis; vaillanti; vaniformis; xantha; crassa; 
radiculosa.  
Ganoderma applanatum; brownii; oregonense.  
Trametes cervina; elegans; hirsuta; ochracea; 
pubescens; suaveolens; trogii.  
Albatrellus arellaneus; caeruleoporus; ellisii; 
flettii; ovinus; syringae; Byssoporia terrestris; 
Polyporoletus sublividus; dispansas; 
skamanius; subrubescens.  
Hericium abietis; americanum; coralloides; 
Dentipellis fragilis.  
Thelephora americana; caryphyliea; intybacea; 
mollissima; palmata; regularis; terrestris; 
caespitulans; scissilis.  
Presently unknown  
Table generated by Dr. Chow Lee and Dr. Keith Egger. 
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1.6  Research Goals 
Fungi belonging to phylum Basidiomycota are primary targets for biological activity 
assessment due to the high numbers of biologically active compounds being reported 
(Wasser, 2002).There are numerous wild mushrooms in BC that have never been 
reported or studied for their biological activity (Table 1.3). Targeting BC wild mushrooms 
is expected to open the gate for discovery of novel anti-cancer compounds. It is known 
that these mushrooms possess two categories of bio-active compounds: the high and 
low molecular weight compounds. High molecular weight polysaccharides (including 
protein-polysaccharide complexes) are reported to reduce the cell viability and also to 
interact non-specifically with the immune system to upregulate or downregulate various 
aspects of host response (Lull et al., 2005), while low molecular weight compounds can 
diffuse through the cell membrane, and act on specific signal transduction pathways 
(Zaidman et al., 2005).  
The goals of my research were: (i) collection and identification of BC wild 
mushrooms, (ii) investigation of various solvent extracts from selected British Columbian 
wild mushrooms for their potential anti-proliferative and immuno-modulatory activity, and 
(iii) purification and characterization of anti-proliferative compound(s).  
To do so, the first major research goal was to collect, identify, and extract several 
BC wild mushrooms. Since the primary goal of the research was to discover novel anti-
cancer compounds, the mushrooms found were grouped into three different categories 
at the outset of this research. The three categories are as follows: Group A – 
mushrooms found in BC as well as other countries that are known to have anti-cancer 
properties; Group B – mushrooms found in BC that are related to Group A but have not 
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been investigated; and Group C – mushrooms unique to BC that have never been 
tested (Table 1.3). 
After collection of the BC wild mushrooms, they were identified using two different 
methods. The first method was macro-morphological identification, using morphological 
characteristics like shape, size, color, location etc. to identify the mushrooms. The 
second method was DNA sequencing. Before moving ahead to extraction, the 
mushrooms were categorized as per Table 1.3. Special emphasis was placed on 
mushrooms belonging to group B and C, to elevate the chances of discovering novel 
anti-cancer compounds. 
     The second major research goal was to extract the selected mushrooms and 
subject them to bioassay screening for anti-proliferative and immuno-stimulatory 
activity. A four-solvent extraction scheme adopted from Mizuno et al. (1999), was used 
for extraction. The extracts obtained were subjected to 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay that is a colorimetric assay indicative of anti-
proliferative activity. Further, to screen the extracts for immuno-modulatory activity, they 
were subjected to Enzyme Linked Immunosorbent Assay (ELISA).  
  The third and final research goal was to select an extract and further purify it. Size-
exclusion and anion-exchange chromatography were employed to further separate anti-
proliferative compounds to generate relatively pure compounds. To understand the bio-
chemical nature of the purified bio-active compound(s), several chemical and biological 
assays were performed.  
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Chapter 2   
Collection, identification, extraction and assessment of anti-
proliferative and immuno-stimulatory activities of five 
species of British Columbia wild mushrooms 
 
This chapter includes the process of procurement of the British Columbia (BC) wild 
mushrooms from several locations. Additionally, this chapter also encompasses the 
experiments carried out for macro/micro-morphological work and DNA characterization 
to identify the collected mushrooms, multi-solvent extraction, and screening of the 
fractions obtained for anti-proliferative and immuno-stimulatory activities. 
2.1 Collection and identification of BC wild mushrooms 
2.1.1 Collection of BC wild mushrooms 
 Collection of BC wild mushrooms was carried out at several locations. The warm 
and moist weather conditions between April and October of 2013, 2014, and 2015 made 
it the best time for collection. Mushroom fruiting bodies do not grow for the remainder of 
the year due to snow and colder conditions during winter. The location and conditions 
around the collection sites were noted.  
The book “Mushrooms Demystified” by David Aurora (1986) was used as a field 
guide for initial identification of mushroom species. Photographs of mushrooms 
collected were taken prior to detachment from the substrate. A pocket knife was used to 
detach the mushroom from the substrate to which it was attached. All the morphological 
descriptions such as shape, size, color, location, type of substrate the mushroom was 
found on, etc. were noted. A paper bag was used for temporary storage of the 
mushroom samples until the samples were transported to the lab for further processing. 
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A few BC wild mushroom samples were collected and provided by Drs. Keith Egger and 
Hugues Massicotte. These samples were kept frozen at -80°C.  
 For further analysis, the mushrooms were dried in a conventional oven at 55°C 
for 3-4 days until the mushrooms were completely dried. The dried mushrooms were 
then pulverized using a domestic grade food processor and converted into powder. For 
woody conks, such as Phellinus igniarius, a hammer mill was used to pulverize the 
samples. The powder was then stored at room temperature in airtight bags to avoid 
contamination. 
2.1.2 Macro-morphological identification 
Macro-morphological identification refers to identification based on morphological 
details and characteristics of the collected mushroom samples. Various classes of 
mushrooms exhibited multiple morphological differences, which helped to differentiate 
between mushrooms for preliminary identification of the samples. The book 
“Mushrooms Demystified” by David Aurora (1986) was referenced to narrow down the 
identification of the mushroom samples to family level. 
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protocol provided by the manufacturer. Agarose gel electrophoresis was performed to 
further confirm successful isolation of the DNA from mushroom samples. One percent 
agarose gel (Thermo Scientific, MA, USA) were prepared using TRIS borate – EDTA 
(TBE) buffer and DNA was visualized with ethidium bromide staining under UV light. 
Five µL of the isolated DNA samples from different mushroom samples were mixed with 
2 µL of DNA loading dye. The samples which possessed DNA were subjected to PCR 
(Polymerase Chain Reaction). The DNA Plus ladder (Life Technologies, CA, USA) was 
used to assess the size of PCR product used for DNA identification, the ITS2 DNA 
barcoding region. The ITS exhibits the high degree of vatiation compared to other genic 
regions, hence PCR was used to amplify this region for DNA sequencing analysis and 
species identification. ITS3 and NLB4 (Integrated DNA Technology, IA, USA) primers 
were used to amplify the sequences from the mushroom samples. 
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Mastermix used for PCR contains the following 
DNA template 100 ng   Thermocycler program 
Thermopol buffer 3.5 µL    1) 95°C for 5 min 
dNTP’s (2mM) 3.5 µL    2) 95°C for 1 min 
ITS3 primer  100 ng   3) 52°C for 1 min 
NLB4 primer  100 ng   4) 72°C for 1min 
Taq polymerase 0.5 µL    5) Repeat 1-4 for 29 times 
Nucleasefree water 35 µL    6) 72°C for 5 min 
 
Table 2.1: PCR primers used in the amplification of the ITS 2 sub-region of the fungal 
DNA isolated from the BC wild mushrooms. 
Region Primer DNA Sequence 
ITS 2 ITS-3 5’-GCATCGATGAAGAACGCAGC-3’ 
ITS 2 NLB-4 5’-GGATTCTCACCCTCTATGAC-3’ 
 
 The exponentially amplified DNA samples were further subjected to gel 
electrophoresis for confirmation of DNA amplification and to obtain sufficient quantity for 
DNA sequencing. PCR products with visible amplicons were subjected to cleaning and 
DNA sequencing as described below.   
Figure 2.2:  Depiction of binding positions of various primers commonly used on 
ribosomal cassettes. (Hennell et al., 2012; Martin & Rygiewicz, 2005) 
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 QIAquick® (QIAGEN, Germany) PCR cleaning kit was used to clean the post-
PCR amplified DNA products. After cleaning the PCR products, the samples were sent 
for DNA sequencing to the Northern Analytical Laboratory Services (UNBC). The 
chromatogram received after DNA sequencing was analyzed using Chromas light© 
2.1.1 software (Technelysium Pty Ltd.).  
  The DNA sequences of the mushroom samples were matched to the sequences 
present in the Basic Local Alignment Search Tool (BLAST). A nucleotide BLAST of the 
DNA sequences of the mushroom samples was performed to confirm the mushroom 
species.  
2.2  Methodology – Chemical extraction of BC wild mushrooms 
2.2.1 Manual extraction scheme as followed as per Mizuno et al. (1999)  
 A four-solvent extraction system described by Mizuno (1999) was used. About 
150 g of mushroom powdered sample was weighed and suspended in 1.5 L of 85% 
ethanol (aqueous) in a 2 L Erlenmeyer flask. The mixture was extracted at 65°C for 3 
hrs. The resulting solution was then filtered using a Buchner funnel and # 3 Whatman® 
(Whatman plc, UK) filter paper.  
 The resulting filtrate was then condensed using rotary evaporator Rotavapor® 
(BÜCHI Labortechnik, Switzerland) at 65°C until approximately 125-150 mL solution 
remained. The condensed solution’s pH was adjusted to 7, using 12 M hydrochloric acid 
(HCl) and 5% sodium hydroxide (aq). After pH adjustment, the condensed solution was 
slant frozen at -80°C and lyophilized using FREEZONE freeze dryer (Labconco, MO, 
USA) at -52°C and 0.02 Torr, for 3 days, until a fine powder remained. This fine powder 
was labeled as “Fraction 1”. 
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 The above process was repeated using the remaining residue from the ethanol 
extraction. The sequential extractions were performed using 50% methanol, water and 
5% sodium hydroxide. The lyophilized powder obtained from the 50% methanol, water, 
and 5% sodium hydroxide extractions were labeled as Fraction 2, 3, and 4 respectively. 
The summary of extraction scheme is detailed in Figure 2.3. 
 
Figure 2.3: Extraction scheme used to extract BC wild mushrooms. 
2.2.2 High-pressure extraction using BÜCHI SpeedExtractor® E916  
 Three solvent extraction system described by Mizuno (1999) was used. The 
sample holder section was heated to 65°C. About 40 mL of samples could be loaded 
into the sample holder cells. A mixture of 20 mL powdered mushroom sample and 20 
mL of 0.3-0.8 mm fat-free quartz sand (BÜCHI Labortechnik, Switzerland) was loaded 
22 
 
 
onto the sample holder cells to avoid clogging. Sample holders were secured with filter 
papers before packing to avoid leakage of fine particles during extraction. The sample 
holder cells were placed in the extractor. An extraction protocol was designed using the 
user interface present on the extractor. The samples were then subjected to four 
extraction cycles with 3 solvents (85% ethanol, 50% methanol, and water). The 
extraction cycles are described below. 
Heat-up with solvent    1 min. 
Hold time with sample    15 mins. 
Discharge time     4 mins.  
Flushing to the sample holder   15 mins. 
Flush with solvent     1 min.  
Flushing with gas     3 mins.  
 
 The extracts obtained were condensed using rotary evaporator Rotavapor® 
(BÜCHI Labortechnik, Switzerland) at 65°C until approximately 30-50 mL solution 
remained. The condensed solution was then pH neutralized to 7, using 12 M HCl and 
5% sodium hydroxide. After pH adjustment, the condensed solution was slant frozen at 
-80°C and lyophilized using FREEZONE freeze dryer (Labconco, MO, USA) at -52°C 
and 0.02 Torr, for 3 days, until a fine powder remained. This fine powder was labeled as 
Fraction 1, Fraction 2, and Fraction 3 for 85% ethanol, 50% methanol, and hot water 
respectively.  
 Extraction with 5% sodium hydroxide was not performed using the extractor 
because the sodium hydroxide corrodes the internal lines carrying the solvents. The 5% 
sodium hydroxide extraction was performed manually as described above. 
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2.3 Methodology – Assessment of anti-proliferative and immuno-stimulatory 
activities 
2.3.1 Assessment of dose and time-dependent anti-proliferative activity 
 Dose-dependent MTT assay: HeLa (ATCC®) (cervical cancer cells) culture was 
maintained using Lonza Eagle’s Minimum Essential Medium (VWR, Mississauga, ON, 
CA). Trypsin-EDTA (0.25%) was used to trypsinize the cells adhered to the flask. A 
haemocytometer was used to count the cell density. Approx. 1.5 X 104 cells were plated 
on each well in 96-well plates. The plated cells were then incubated at 37°C in 5% CO2 
atmosphere for 24 hour.  
 On the following day, lyophilized mushroom samples were prepared and added 
to the cells. The dried mushrooms fractions were first reconstituted in a solvent that 
could completely solubilize the mushroom fractions. Twenty mg/mL stock solutions of 
the crude mushroom fractions were prepared. Further, the stock solutions were 
adjusted to pH 7 using hydrochloric acid (12 M) or 5% sodium hydroxide. The pH 
adjusted stock solution was then filter sterilized using 0.2 µm filter (Sarstedt, 
Nümbrecht, Germany). Using the 20 mg/mL stock solutions, dilutions were made and 
added to each well, such that the final working concentrations were 0.2 mg/mL, 0.4 
mg/mL, 0.6 mg/mL, 0.8 mg/mL, and 1.0 mg/mL. Six replicates of each sample and 
control (same solvent in which the fractions were reconstituted) were included.  
 The cells were incubated with mushroom fractions for 48 hours. After the 
incubation, 50 µL of 1 mg/mL MTT solution was added to each well and incubated for 
another 3 hours. The supernatant was removed from each well and 200 µL of Di-Methyl 
Sulfoxide (DMSO) was added to each well, to dissolve the formazan crystals. The 96-
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well plate was then subjected to absorbance reading at 570 nm using SYNERGY 2 
multi-plate reader (BioTek®, VT, USA).  
 Table 2.2: Table displaying general 96-well plate layout for anti-proliferative assay 
of wild BC mushroom samples. 
X X X X X X X X X X X X 
X None Control Fr. 1: 0.2 mg/mL 
Fr. 1: 0.4 
mg/mL 
Fr. 1: 0.6 
mg/mL 
Fr. 1: 0.8 
mg/mL 
Fr. 1: 1 
mg/mL X X X X 
X None Control 
Fr. 1: 0.2 
mg/mL 
Fr. 1: 0.4 
mg/mL 
Fr. 1: 0.6 
mg/mL 
Fr. 1: 0.8 
mg/mL 
Fr. 1: 1 
mg/mL X X X X 
X None Control 
Fr. 1: 0.2 
mg/mL 
Fr. 1: 0.4 
mg/mL 
Fr. 1: 0.6 
mg/mL 
Fr. 1: 0.8 
mg/mL 
Fr. 1: 1 
mg/mL X X X X 
X None Control 
Fr. 1: 0.2 
mg/mL 
Fr. 1: 0.4 
mg/mL 
Fr. 1: 0.6 
mg/mL 
Fr. 1: 0.8 
mg/mL 
Fr. 1: 1 
mg/mL X X X X 
X None Control 
Fr. 1: 0.2 
mg/mL 
Fr. 1: 0.4 
mg/mL 
Fr. 1: 0.6 
mg/mL 
Fr. 1: 0.8 
mg/mL 
Fr. 1: 1 
mg/mL X X X X 
X None Control 
Fr. 1: 0.2 
mg/mL 
Fr. 1: 0.4 
mg/mL 
Fr. 1: 0.6 
mg/mL 
Fr. 1: 0.8 
mg/mL 
Fr. 1: 1 
mg/mL X X X X 
X X X X X X X X X X X X 
 
In time-dependent MTT assay, 0.75 X 104 HeLa cells were plated on 7 different 
96-well plates. Each plate was treated with mushroom fractions 24hrs after plating the 
HeLa cells. The plated cells were then incubated in a 5% CO2 incubator for 24, 48, 72, 
96, 120, and 144 hours. The MTT assays were conducted on different days for different 
plates as described above. 
 The activity of various fractions was measured in % cell viability compared to that 
of a control. Standard deviation was the error of the MTT bioassay. Kaleidagraph© 
version 4.03 (Synergy Software) was used to generate the graph for the acquired data. 
The calculation model used to process the raw data from time and dose-dependent 
assay is mentioned in Appendix vii. 
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2.3.2 Assessment of immuno-stimulation by measuring TNF-alpha 
production from macrophage cells  
Supernatant collection: RAW 264.7 (murine macrophage cells) cells are 
cultivated using BioWhittaker® Dulbecco’s Modified Eagle’s Medium (DMEM) (Lonza, 
MD, USA) until 50-60% confluent. Life Technology TrypLE™ Express (Thermo Fisher 
Scientific, MS, USA) was used to trypsinize the cells adhered to the flask.  Raw 264.7 
cells were plated at 25 X 104 cells per well in 96-well plates. The plated cells were then 
incubated in 5% CO2 overnight.  
 After overnight incubation, the medium was removed and the plated cells were 
washed with 200 µL BioWhittaker® Phosphate Buffer Saline (PBS) (Lonza, MD, USA). 
One hundred µL of DMEM was added to the wells containing RAW 264.7 cells. 100 µL 
of 1 mg/mL filter sterilized mushroom fraction and 500ng/mL Lipopolysaccharides (LPS) 
was added to the RAW 264.7 cells and left for incubation at 37°C and 5% CO2 for 6 
hours. After incubation, 150 µL of the supernatant was collected. The collected 
supernatant was centrifuged at 4°C and 200 x g using an Allegra® X-15R, benchtop 
centrifuge (Beckman Coulter, CA, USA). The supernatant was then transferred to 
another 96-well plate, labeled and stored at -80°C overnight before performing ELISA. 
 ELISA Assay: BD OptEIA™ Mouse TNF (Mono/Mono) ELISA Set and Reagent 
Set B (BD Biosciences, CA, USA) were used to perform ELISA. BD OptEIA™ Mouse 
TNF (Mono/Mono) ELISA Set includes; 1) Anti-mouse TNF monoclonal antibody 
(Capture antibody), 2) Biotinylated Anti-Mouse TNF monoclonal antibody (Detection 
antibody, 3) Streptavidin-horseradish peroxidase conjugate (Enzyme reagent), and 4) 
Recombinant mouse TNF (Standards). BD OptEIA™ Mouse TNF (Mono/Mono) 
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Reagent Set B includes 1) Substrate reagent A, 2) Substrate reagent B, 3) Wash 
concentrate buffer (20X), 4) Stop solution, 5) Assay diluent, and 6) Coating buffer.   
Capture antibody was added to coating buffer in a 1:500 ratios. One hundred µL 
of capture antibody was then added to the microwells in 96-Well Microtiter™ 
polystyrene plates (Thermo Fisher Scientific, MA, USA) to coat it with the Anti-mouse 
TNF monoclonal antibody. The plate was sealed and incubated at 4°C overnight. On the 
following day, the antibody was removed after overnight incubation, and the supernatant 
collected from the RAW 264.7 cells were allowed to thaw on ice. The microwells on the 
96-well plate were washed with 300 µL of 1X wash buffer (prepared by diluting wash 
concentrate buffer 20 times using water) for three successive times. The plates were 
then blocked using 200 µL assay diluent, sealed, and then left for incubation at room 
temperature for 1 hour. 
 While waiting for the plates to be blocked, the supernatant was diluted three 
times and the LPS diluted 12 times using assay diluent. The TNF-alpha standard was 
prepared at 1000, 500, 250, 125, 62.5, 31.3, and 15.6 pg/mL for a standard curve 
through serial dilution using assay diluent and 155ng/mL standard stock solution.  
 After blocking the plates with assay diluent, the assay diluent was discarded and 
the 96-well plate was washed with 1X wash buffer for three successive times. After the 
wash, 100 µL of the standard and samples were added to the 96-well plates. The TNF-
alpha standards were placed in triplicates and the samples in six replicates for better 
optimization. The 96-well plate was then sealed and left for incubation at room 
temperature for 2 h.   
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 After 2 h of incubation, the standard and sample supernatants were discarded, 
and wells were washed five times with 300 µL 1X wash buffer. One hundred µL of 
working detector (detection antibody + Streptavidin-horseradish peroxidase conjugate) 
was added to the appropriate microwells on the 96-well plate and left for incubation at 
room temperature for 1 h.  
 The incubation step was followed by seven washing steps with 1X wash buffer. 
One hundred µL of substrate solution (solution A+B) was added to the wells and left for 
incubation for 30 mins. at room temperature in the dark. Fifty µL of stop solution was 
added to the appropriate micro-wells on the 96-well plate and was subjected to 
absorbance reading at 450 nm and 570nm using SYNERGY 2 (BioTek®, VT, USA). 
The calculations were performed as per the user manual provided by the manufacturer. 
Statistical analysis was performed using One-way ANOVA. Sidak’s or Dunnett’s multiple 
comparisons test was done as post-hoc analysis once the null hypothesis was rejected.       
2.4  Results and Discussion 
2.4.1 Macro-morphological and molecular identification of collected 
mushrooms 
Five different mushroom species were collected at random from different 
locations in British Columbia. The collected mushrooms were subjected to both macro-
morphological and DNA analysis species identification. The following are the results 
obtained from the collection and identification steps. 
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1. Amanita muscaria 
 
Figure 2.4: Amanita muscaria (L.) Lam.  
Collected by:  Dr. Hugues Massicotte and Ankush Barad 
Location:  Moore’s Meadow Park, Prince George, BC, Canada. 
Collected on:  October 2013 and June 2014  
Morphological Characteristics 
Type:   Gilled mushroom fruiting body 
Size:   Cap – 5-25cms, Stem – 5-15cms. 
Shape:  Cap- Flat with white spots,  
Color:   Cap - Red-Orange, Stem – Cream-Yellow, Gills - White 
Gills:  Close, broad, free and adnate 
Spore Deposit: White  
Flesh:  Thick and firm when young 
Habitat:   Was found in a meadow surrounded by tall grass 
Matchmaker Mushroom match: Amanita muscaria 
Sequencing match:  Amanita muscaria (L.) Lam. (1783) 
 
Primer used:  NLB4 and ITS3 
Max score:   562 
Total score:   562 
Query covered:   60% 
Identification:   96% 
Accession:  DQ822791.1 
2. Gyromitra esculenta  
Collected by: Dr. Keith Egger 
Location:  Miworth, Prince George, BC, Canada. 
Collected on: May 2014 
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Identified by: Dr. Chow Lee 
 
Morphological Characteristics: 
Type:   False morels 
Size:   Cap – 3-10cms, Stem – 2-14cms x 1-2cms,  
Color:   Cap – yellowish to dark brown, Stem – brown 
Gills/Pores: 2-4 per mm with angular to tooth shaped,  
Under-cap: White to creamish with rough surface  
Flesh:  thin, pale-colored 
Habitat:   Found on roots or decaying wood chips 
Matchmaker Mushroom match: Gyromitra esculenta (Pers.) Fr. (1849) 
Sequencing match:  Gyromitra esculenta 
 
Primer used:  NLB4 and ITS3 
Max score:   800 
Total score:   800 
Query covered:   70% 
Identification:   96% 
Accession:  AJ544208.2 
3. Paxillus obscurisporus: 
Collected by: Dr. Hugues Massicotte and Dr. Zoe Meletis 
Location:  17th Ave, Prince George, BC, Canada. 
   Forest for the World, Prince George, BC, Canada. 
Collected on: August 2013 and May 2014  
Morphological Characteristics: 
Type:   Gilled mushroom fruiting body 
Size:   Cap – 4-16cms, Stem – 2-5cms x 0.4-3cms. 
Color:   Cap – dark brown, Stem – dark cream - brown, Gills - cream 
Gills:  Close, crowded and forking 
Spore Deposit: Brown to yellow brown  
Flesh:  Thick and firm  
Habitat:   Found densely populated on ground and woods  
Matchmaker Mushroom match: Paxillus obscurisporus/Paxillus involutus 
Sequencing match:  Paxillus obscurisporus (C.Hahn, 1999) 
 
Primer used:  NLB4 and ITS3 
Max score:   776 
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Total score:   776 
Query covered:   85% 
Identification:   95% 
Accession:  HQ207702.1 
4. Phellinus igniarius 
 
Figure 2.5: Phellinus igniarius (L.) Quél (1886) 
Collected by: Dr. Chow Lee and Dr. Wai Ming Li  
Location:  Kitselas, Terrace, BC, Canada. 
Collected on: August 2014 
Identified by: Dr. Wai Ming Li 
  
Morphological Characteristics: 
Type:   Polypores (Conk) 
Size:   Cap – 5-25cms x 2-16cms, Stem – none 
Color:   Cap – dark brown - black, Stem – none, Gills - none 
Gills/Pores: 4-5mm,  
Spore Deposit: White to cream 
Flesh:  Woody with brown color 
Habitat:   Continually appearing single or in small groups on hardwood  
Matchmaker Mushroom match: Phellinus igniarius (L.) Quél (1886) 
Sequencing match:  Phellinus igniarius 
 
Primer used:  NLB4 and ITS3 
Max score:   676 
Total score:   676 
Query covered:   73% 
Identification:   99% 
Accession:  AY558623.1 
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5. Trichaptum abietinum 
 
Figure 2.6: Trichaptum abietinum (Pers. Ex. J.F. Gmel) Ryvarden 
Collected by: Ankush Barad 
Location:  Forest for the World, Prince George, BC, Canada. 
Collected on: October 2013 
 
Morphological Characteristics: 
Type:   Polypores (Conk) 
Size:   Cap – 1-5 cms, Stem – none 
Color:   Cap – gray to black, Stem – none, Gills - none 
Gills/Pores: 2-4 per mm with angular to tooth shaped,  
Spore Deposit: White to cream 
Flesh:  Woody with brown color 
Habitat:   Found annually on decaying hard/softwood 
Matchmaker Mushroom match: Trametes versicolor/Trichaptum abietinum 
Sequencing match:  Trichaptum abietinum (Pers. Ex. J.F. Gmel) Ryvarden 
 
Primer used:  NLB4 and ITS3 
Max score:   826 
Total score:   826 
Query covered:   90% 
Identification:   97% 
Accession:  KC581332.1 
 
 
32 
 
 
2.4.2 Chemical extraction of the BC wild mushrooms 
The collected mushrooms were extracted either manually or using BÜCHI 
SpeedExtractor® as described in section 2.2.1 and 2.2.2. The description of various 
fractions obtained from the extraction is summarized in Table 2.3 below. 
Table 2.3: Summary of fractions obtained upon extraction of the mushrooms. 
Mushroom 
Species 
Amount 
of extract 
used 
(grams) 
Fraction Mass (grams) 
Physical 
appearance 
Reconstituted 
in 
Amanita 
muscaria 13.71 
85% 
Ethanol 
(F1) 
2.0627 Viscous and sticky Ethanol 
50% 
Methanol 
(F2) 
0.7895 Viscous and sticky Water 
Hot water 
(F3) 0.3775 Fine powder Water 
5% Sodium 
hydroxide 
(F4) 
21.886 Chunky powder Water 
Gyromitra 
esculenta 16.17 
85% 
Ethanol 
(F1) 
1.276 Fluffy (Cotton like) Water 
50% 
Methanol 
(F2) 
0.961 Fluffy (Cotton like) Water 
Hot water 
(F3) 0.891 Fine powder Water 
5% Sodium 
hydroxide 
(F4) 
18.239 Chunky powder Water 
Paxillus 
obscurispor
us 
19.452 
85% 
Ethanol 
(F1) 
4.2895 Coarse powder Water 
50% 
Methanol 
(F2) 
2.295 Coarse powder Water 
Hot water 
(F3) 0.417 
Fluffy (Cotton 
like) Water 
5% Sodium 20.162 Chunky Water 
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hydroxide 
(F4) 
powder 
Phellinus 
igniarius 11.296 
85% 
Ethanol 
(F1) 
0.882 Fluffy (Cotton like) Ethanol 
50% 
Methanol 
(F2) 
0.857 Fluffy (Cotton like) Water 
Hot water 
(F3) 0.722 Fine powder Water 
5% Sodium 
hydroxide 
(F4) 
9.002 Chunky powder Water 
Trichaptum 
abietinum 10.629 
85% 
Ethanol 
(F1) 
0.482 Fluffy (Cotton like) Water 
50% 
Methanol 
(F2) 
0.544 Fluffy (Cotton like) Water 
Hot water 
(F3) 0.336 
Fluffy (Cotton 
like) Water 
5% Sodium 
hydroxide 
(F4) 
4.33 Chunky powder Water 
 
2.4.3 Dose and time-dependent anti-proliferative activity of mushroom 
fractions on HeLa cell 
The mushroom fractions obtained from the extraction were reconstituted in an 
appropriate solvent as shown in Table 2.3. HeLa cells were first subjected to dose-
dependent MTT assay experiments. Upon obtaining the results from the dose-
dependent MTT experiments, selected concentration of the mushroom fractions were 
then used to perform time-dependent MTT assays.  
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Figure 2.7: Assessing anti-proliferative activity from extracts of Amanita muscaria. (A) 
Dose-dependent assay for Fractions 1-4 of Amanita muscaria. The graph is representative 
results from two different replicate (n=2). (B) Time-dependent assay for bio-active Fractions 1 
and 4 at 0.5 mg/mL. Graph is representative results from two different replicate (n=2). Error 
bars are standard deviation. 
 
 Results from the dose-dependent MTT assay of Fractions 1-4 from Amanita 
muscaria are shown in Figure 2.7(A). Fractions 1 and 4 significantly reduce cell viability 
to 15% at 0.4 and 0.8 mg/mL respectively. By contrast, Fractions 2 and 3 did not appear 
to have any significant effect on cell viability; decreasing to only 80%. Fractions 1 and 4, 
that exhibited strong anti-proliferative activity were further subjected to a time-
dependent MTT assay at the concentration of 0.5 mg/mL. Results from the time-
dependent MTT assay showed that Fraction 1 reduced cell viability to less than 5% after 
30 hours of treatment. On the other hand, cell viability was reduced to only 70% by 
Fraction 4 on day 5 (120 hours).   
 Figure 2.8 shows the result from the dose-dependent MTT assay of Gyromitra 
esculenta. The results show that Fraction 2 (at 0.8 mg/mL) suppressed the cell viability 
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to only 60%. Since the anti-proliferative activity exhibited by all the fractions were 
considered weak (less than 50%), time-dependent MTT assay was not performed on all 
the fractions from Gyromitra esculenta.  
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Figure 2.8: Assessing anti-proliferative activity from extracts of Gyromitra esculenta. 
Dose-dependent assay for Gyromitra esculenta. The graph is representative results from two 
different replicate (n=2). Error bars are standard deviation. 
 The results obtained from dose-dependent MTT assay performed using all the 
fractions of Paxillus obscurisporus are shown in Figure 2.9(A). The results show that 
Fractions 3 and 4 reduced cell viability to about 50% at 0.4 and 1.0 mg/mL respectively. 
By contrast, the anti-proliferative activity exhibited by Fractions 1 and 2 was minimal, 
reducing HeLa cell viability to less than 20%. Hence, HeLa cells were treated with bio-
active Fractions 3 and 4 at 0.5 mg/mL for time-dependent MTT assay. Figure 2.9(B) 
shows that both Fractions 3 and 4 significantly reduced cell viability by day 1 and this 
persisted up to day 5. 
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Figure 2.9: Assessing anti-proliferative activity from extracts of Paxillus obscurisporus. 
(A) Dose-dependent assay for Fraction 1-4 of Paxillus obscurisporus, where graph is 
representative results from two different replicate (n=2). (B) time-dependent assay for active 
fraction 3 and 4 at 0.5 mg/mL, where graph is representative results from two different replicate 
(n=2). Error bars are standard deviation.  
 Dose-dependent MTT assay on fractions from Phellinus igniarius shows that 
Fractions 1 and 3 exhibited strong anti-proliferative activity. As shown in Fig 2.10(A), 
Fraction 1 reduced cell viability to 20% at 0.6 mg/mL and Fraction 3 reduced cell 
viability to 40% at 0.1 mg/mL. Fractions 2 and 4 reduced cell viability to about 60%. 
Figure 2.10(B) shows that Fraction 1 at the concentration of 0.2 mg/mL and Fraction 3 
at 1 mg/mL significantly reduced cell viability to 10% by day 1 and the effect persisted 
up to day 5. 
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Figure 2.10: Results of MTT assay of Phellinus igniarius. (A) Dose-dependent assay for 
Fractions 1-4 of Phellinus igniarius. The graph is representative results from two different 
replicate (n=2). (B) Time-dependent assay for active Fraction 1 at 0.2 mg/mL and Fraction 3 at 
1 mg/mL. The graph is representative results from two different replicate (n=2). Error bars are 
standard deviation.  
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Figure 2.11: Results of MTT assay of Trichaptum abietinum. (A) Dose-dependent assay for 
Fraction 1-4 of Trichaptum abietinum. The graph is representative results from two different 
replicate (n=2). (B) time-dependent assay for active Fraction 1 at 0.5 mg/mL. The graph is 
representative results from two different replicate (n=2). Error bars are standard deviation. 
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 Finally, results from the dose-dependent assay of Trichaptum abietinum are 
shown in Fig 2.11(A).  The results show the moderate anti-proliferative activity from 
Fractions 1 and 3 that reduced cell viability to about 40% at 1 mg/mL each. On the other 
hand, Fractions 2 and 4 showed weak anti-proliferative activity. Fraction 2 reduced cell 
viability to only 90% and Fraction 4 to only 70%. The time-dependent MTT assay in Fig 
2.11(B) shows that the bio-active Fraction 1 retained its moderate anti-proliferative 
activity. Fraction 1 was shown to reduce cell viability to 80% over a course of 5 days.  
 The loss in anti-proliferative activity observed in Fraction 1 from Trichaptum 
abietinum and Fraction 4 from Amanita muscaria, could result of chemical degradation 
because of the 2-week time period between dose-dependent MTT assay and time-
dependent MTT assay.  Although all the mushrooms fractions were stored at 4°C, it is 
possible that the bio-active molecule(s) could degrade with time. 
2.4.4 Effect of TNF-alpha production in Raw 264.7 macrophage cells upon 
treatment with mushroom fractions 
Immuno-stimulatory activity of the mushroom extracts was assessed by their ability 
to induce TNF-α production in Raw 264.7 macrophage cells. TNF- α levels were 
measured using an Enzyme Linked Immunosorbent Assay (ELISA). 
As seen in Figure 2.12(A), Fraction 4 from Amanita muscaria induced TNF-α to 
about 500 pg/mL in Raw264.7 cells after 6 hours of treatment. The other fractions from 
Amanita muscaria had little or no effect. The negative controls water and ethanol 
induced TNF-α level to only 99 pg/mL and 30 pg/mL respectively. Figure 2.12(B) shows 
that Fraction 1 from Gyromitra esculenta, induced TNF-α level to approximately 2,000 
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pg/mL, whereas Fractions 2 and 3 could induce it over 3,000 pg/mL. On other hand, 
fraction 4 had no effect. 
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Figure 2.12: Effect of fractions from A.muscaria (A) and G.esculenta (B) on TNF-α 
production in Raw 264.7 macrophage cells. LPS was positive control, ethanol was negative 
control for Fraction 1 and water was negative control for the other fractions. The graphs are 
representative results from 2 different replicates (n=2) (*, P<0.0001). 
 Figure 2.13(A) shows that Fractions 2,3, and 4 from Paxillus obscurisporus 
induced TNF-α levels to 3,120 pg/mL, 3,350 pg/mL, and 4,425 pg/mL respectively. 
Fraction 1 showed very weak bio-activity with an induction of 309 pg/mL. Water serving 
as a negative control induced TNF-α to only 42 pg/mL, suggesting that water had no 
effect on Raw 264.7 cells. The strongest immuno-stimulatory activity was demonstrated 
by the 4th fraction from Paxillus obscurisporus, with an induction of 4,425 pg/mL TNF-α. 
Figure 2.13(B) shows that all the fractions from Phellinus igniarius had very weak or no 
bio-activity with regards to induction of TNF- α to less than 150 pg/mL.  
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Figure 2.13: Effect of fractions from Paxillus obscurisporus (A) and Phellinus igniarius 
(B) on TNF-α production in Raw 264.7 macrophage cells. LPS was positive control, and 
water was negative control. The graphs are representative results from 2 different replicates 
(n=2) (*, P<0.0001). 
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Figure 2.14: Effect of fractions from Trichaptum abietinum on TNF-α production in Raw 
264.7 macrophage cells. LPS was positive control, water was negative control. The graph is 
representative results from 2 different replicates (n=2) (*, P<0.0001). 
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Finally, results from the immuno-stimulatory ELISA assay on fractions of 
Trichaptum abietinum are shown in Figure 2.14. Fraction 2 induced TNF-α levels to 
2,530 pg/mL, indicating a strong immuno-stimulatory activity. Fractions 1 and 4 
exhibited weak activity by inducing TNF-α levels to 256 pg/mL and 312 pg/mL 
respectively. The results for Fraction 3 are unavailable as Fraction 3 was obtained at a 
very low amount during the chemical extraction. The amount available was consumed 
for anti-proliferative activity assessment experiments.  
2.4.5 A summary of biological activity exhibited by mushroom in this 
study and their previously reported bio-activities   
After biological activity screening of the collected mushrooms, all the bio-activity 
screening results were examined to select a mushroom fraction for further purification. 
The criteria considered included 1) strong bio-activity, 2) the novelty of the mushroom 
species (mushroom species unreported for anti-cancer activity would possess novel 
anti-cancer molecules), 3) availability in Northern BC, and 4) amount of dry powdered 
bio-active fraction obtained from extraction. The following is the summary of the bio-
activities of five mushrooms generated in this study and their reported activities in the 
literature. 
 As shown in Table 2.4, Fraction 1 from Amanita muscaria reduced the cell 
viability by 89% and Fraction 4 exhibited very weak immuno-stimulatory activity with an 
induction of 585 pg/mL. Amanita muscaria is known to exhibit anti-tumor and immuno-
stimulatory activities (Kiho et al., 1993; Wasser, 2002). Since it is a well-characterized 
mushroom, any fractions extracted from this mushroom would have a low possibility of 
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containing new anti-cancer compound(s). For this reason, none of the fractions obtained 
from Amanita muscaria were selected for further purification. 
Table 2.4: Summary of bio-activity of BC wild mushrooms. 
Mushroom Species Fraction 
Anti-
proliferative 
activity 
(% inhibition) 
Immuno-
stimulatory activity 
(pg/mL ofTNF-α 
produced) 
Amanita muscaria 
85% Ethanol 
(F1) 89% 14 
50% Methanol 
(F2) 16% 29 
Hot water 
(F3) 13% 180 
5% Sodium 
hydroxide (F4) 85% 585 
Gyromitra esculenta 
85% Ethanol 
(F1) 28% 2,015 
50% Methanol 
(F2) 45% 3,210 
Hot water 
(F3) 24% 3,191 
5% Sodium 
hydroxide (F4) 14% 108 
Paxillus 
obscurisporus 
85% Ethanol (F1) 0% 310 
50% Methanol 
(F2) 24% 3,120 
Hot water (F3) 45% 3,346 
5% Sodium 
hydroxide (F4) 56% 4,425 
Phellinus igniarius 
85% Ethanol (F1) 78% 46 
50% Methanol 
(F2) 45% 85 
Hot water (F3) 59% 55 
5% Sodium 
hydroxide (F4) 35% 126 
Trichaptum abietinum 
85% Ethanol (F1) 55% 256 
50% Methanol 
(F2) 29% 2,530 
Hot water (F3) 58% - 
5% Sodium 
hydroxide (F4) 
9% 312 
43 
 
 
  
Fraction 2 from Gyromitra esculenta exhibited mild anti-proliferative activity by 
inhibiting the cell viability to 55%. On the other hand, Fractions 1, 2, and 3 from 
Gyromitra esculenta exhibited strong immuno-stimulatory activity by inducing TNF-α 
levels to more than 2,000 pg/mL. Gyromitra esculenta has been reported to contain an 
hydrazine derivative toxin named Gyromitrin (Israël, 2012), that is considered to be 
dangerously toxic and carcinogenic. While collecting the supernatant for immuno-
stimulatory ELISA assay, the Raw 264.7 cells treated with fractions from Gyromitra 
esculenta did not appeared to be toxic as compared to control-treated cells. Since there 
have been no previous studies on the immuno-stimulatory activity by Gyromitra 
esculenta, it maybe worthwhile in the future to investigate the immune-stimulatory 
compound(s) from this mushroom species.  
 Fractions 1 and 3 from Phellinus igniarius exhibited strong anti-proliferative 
activity, inhibiting the cell viability by 78% and 59% respectively. Although the anti-
proliferative activity exhibited by these fractions from Phellinus igniarius was strong, it 
has already reported to exhibit strong anti-proliferative activity through possession of 
extracellular endo-polysaccharides (Chen et al., 2011; Song et al., 2008).  Hence, none 
of the extracts obtained from Phellinus igniarius were chosen to purify any anti-
proliferative compound(s). 
   Fractions 1 and 3 from Trichaptum abietinum exhibited moderate anti-
proliferative activity, inhibiting cell viability by 55% and 58% respectively. Fraction 2 
from Trichaptum abietinum exhibited strong immuno-stimulatory activity by inducing 
TNF-α levels to 2,530 pg/mL. Trichaptum abietinum is a wood decay fungus that has 
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not been reported to possess any bio-activity. Although Trichaptum abietinum is 
available in northern BC in abundance, it closely resembles other polypore mushrooms 
like Trametes hirsuta, Trametes biforme, etc. This makes identification and collection of 
large samples of Trichaptum abietinum difficult, and increases the chances of cross 
contamination of this species. Since there are no reports about any bio-activity from 
Trichaptum abietinum, it is a good candidate for further purification study in the near 
future. However, due to the challenges in collecting and identifying this mushroom 
species, Trichaptum abietinum was not pursued further in this study.   
 Finally, Fractions 3 and 4 from Paxillus obscurisporus exhibited moderate anti-
proliferative activity, inhibiting the cell viability by 45% and 56%. Also, Fractions 2, 3, 
and 4 exhibited strong immuno-stimulatory activity by inducing TNF-α levels to 3,120 
pg/mL, 3,346 pg/mL, and 4,425 pg/mL respectively. Paxillus obscurisporus has not 
been reported to have any bio-activity, and is closely related to Paxillus involutus. P. 
involutus has been reported to exhibit anti-proliferative activity by a 28kDa lectin (Wang 
et al., 2013).  
The 4th fraction from Paxillus obscurisporus, exhibited moderate anti-proliferative 
and strong immuno-stimulatory activities. The availability of Paxillus obscurisporus in 
Prince George and the surrounding area, its abundance and the fact that no prior 
studies has been reported on its anti-cancer activity, made Paxillus obscurisporus a 
good candidate for further purification of novel anti-cancer compound(s). Hence, 
Fraction 4 from Paxillus obscurisporus was selected for further study described in 
Chapter 3.    
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By the end of this chapter, two primary goals of this thesis were achieved that 
included: 1) collection and identification of five BC wild mushrooms and 2) extractions 
and bioactivity assessment of fractions extracted from five BC wild mushroom. Through 
the assessment of bioactivity of fractions obtained from five different BC wild 
mushrooms, it was deemed beneficial to further purify and chemically characterize the 
5% sodium hydroxide extract (fraction 4) from Paxillus obscurisporus. The purification 
and chemical characterization of 5% sodium hydroxide extract (fraction 4) is described 
in Chapter 3. 
 
 
 
 
 
 
 
 
 
   
 
 
46 
 
 
Chapter 3  
Purification and chemical characterization of an alkaline 
extract (fraction 4) from Paxillus obscurisporus 
 
Fresh specimens of Paxillus obscurisporus were collected in the late summer of 
2015 by Drs. Keith Egger and Hugues Massicotte and used to reassess biological 
activity. The purpose of this collection was to assess the reproducibility of bio-activity 
previously shown by Paxillus obscurisporus in Chapter 2. Thereafter, the goal described 
in this chapter was to perform purification and chemical characterization of the bio-
active compounds present in 5% sodium hydroxide (NaOH) extract of Paxillus 
obscurisporus collected in 2015.  
3.1  Methodology – Identification, extraction and biological activity screening 
of new batches of Paxillus obscurisporus  
3.1.1 Micro-morphological identification of the collected Paxillus 
obscurisporus using ITS2 and NLB4 primers 
The methodology for genetic identification of Paxillus obscurisporus using ITS2 
and NLB4 primers was described in section 2.1.3 of Chapter 2. 
3.1.2 Assessment of bio-activity of Paxillus obscurisporus collected in 
2014 
The anti-proliferative MTT assays and immuno-stimulatory ELISA assays were 
performed to assess the bio-activity of the 5% NaOH extract from Paxillus 
obscurisporus. The protocol used for the MTT assay is described in section 2.3.1 of 
Chapter 2. Whereas, the immuno-stimulatory activity of Paxillus obscurisporus was 
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confirmed by performing Sandwich ELISA assay and the protocol used is described in 
section 2.3.2 of Chapter 2.  
3.2  Methodology – Purification of fraction 4 from Paxillus obscurisporus using 
size-exclusion chromatography 
3.2.1 Size-exclusion/gel-permeation chromatography using a 20mL size 
Sephadex™ LH-20 column 
Sephadex™ LH-20 (GE Healthcare, Quebec) was the liquid chromatography 
medium used for size-exclusion chromatography. The resin was swelled in degassed 
water for three to five hours. For each gram of dry resin, 4 mL water was used for the 
resin to swell. A total of 5 g of the resin was swollen in 20 mL of water.  
To make a 20 mL size column, a 25 mL serological pipette (Sarstedt, Nümbrecht, 
Germany) was used to form a column. A 200 μL micropipette tip was loaded with glass 
wool and placed at the bottom of the 25 mL serological pipette to form a packing to clog 
the resin at the column end. The swollen Sephadex™ LH-20 was loaded onto the 
column in a continuous flow. A glass rod was placed at the mouth of the column to 
ensure continuous flow of resin, so that air would not get trapped while loading the resin 
onto the column. About 3-5 bed volumes of water were flushed through the column to 
ensure proper packing of the column. 
The recommended sample volume for Sephadex™ LH-20 is 2% of the total bed 
volume. Therefore, 2 mL of 20 mg/mL stock solution from 5% NaOH extract of Paxillus 
obscurisporus was prepared and filtered using a 0.45 μm filter (Sarstedt, Nümbrecht, 
Germany) to remove any large particulates. After the sample was loaded, water was run 
through the column continuously and twenty 1 mL fractions were collected. All the 
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collected fractions were then filter sterilized using a 0.2 μm filter (Sarstedt, Nümbrecht, 
Germany) and stored at 4°C. 
3.2.2 Purification using 120mL Sephadex™ LH-20 on a C16/70 column 
To attain a higher yield of the purified fractions, a larger C16/70 column (GE 
Healthcare, Quebec) with a total volume of 140 mL was used. About 30 g of dry 
Sephadex™ LH-20 was swollen for about three to five hours using approximately 140 
mL of degassed water to attain 120 mL of total bed volume. An AC 16 (GE Healthcare, 
Little Chalfont, UK) flow adapter was placed on the bottom of the column. The adapter 
maintains the pressure and flow rate of the buffer in the column, while preventing the 
backflow of the buffer in the column. The swollen resin was loaded onto the column 
using a RC 16 (GE Healthcare, Little Chalfont, UK) reservoir and allowed to settle. The 
AC 16 adapter was placed on the top-end of the column. The tubing attached to the AC 
16 flow adapter was connected to a P-50 pump (Pharmacia Biotech, Sweden) that 
maintains the buffer flow rate. The buffer flow rate was maintained at 2 mL/min to 
ensure proper column packing. A three-way stopcock was used, to facilitate the loading 
of samples onto the column. 
A 2.5 mL sample solution of 40 mg/mL was prepared by re-suspending the 
lyophilized 5% NaOH extract from Paxillus obscurisporus in water. The sample solution 
was centrifuged at 100 x g for 3 mins using Allegra® X-15R, benchtop centrifuge 
(Beckman Coulter, CA, USA) to get rid of insoluble particulate. The three-way stopcock 
was directed from the idle port to the column where the syringe containing the sample 
solution was introduced. The sample was loaded onto the column at a flow rate of 1 
mL/min.  
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After loading the sample solution onto the column, the stopcock direction was 
changed to direct the flow of the buffer from the pump to the column. The flow rate of 1 
mL/min was maintained while the sample was running in the column. Twenty fractions 
with a fraction size of eight mL were collected and filter sterilized using a 0.2 μm filter 
(Sarstedt, Nümbrecht, Germany) and stored at 4°C. After each use, the column was 
washed with five-bed volumes of water at 1.5 mL/min flow rate. This ensured the 
reusability of the resin present in the column and prevented cross contamination. 
3.2.3 Purification using 530mL Sephadex™ LH-20 on a C26/100 column 
To attain an even higher yield of the purified fractions, a larger C26/100 column 
(GE Healthcare, Quebec) having a total volume of 530 mL was used. About 125 g of dry 
Sephadex™ LH-20 was swollen for about three to five hours using approximately 500 
mL of degassed water. An AC 26 (GE Healthcare, Quebec) flow adapter that maintains 
the pressure, flow rate and avoids backflow of the buffer, was placed on the bottom of 
the column. The swollen resin was loaded onto the column using a RC 26 (GE 
Healthcare, Quebec) reservoir and allowed to settle in the column. Once the swollen 
resin was settled in the column, the packing was done by placing another AC 26 flow 
adapter on the top-end of the column. The tubing attached to the AC 16 flow adapter 
was connected to a P-50 pump (Pharmacia Biotech, Sweden) that maintained the buffer 
flow rate. While packing the column, the flow rate was maintained at 2 mL/min, and a 
three-way stopcock was used to load the samples onto the column. 
A 10 mL sample solution at 40 mg/mL was prepared by re-suspending the 
lyophilized 5% NaOH extract from Paxillus obscurisporus in water. The sample solution 
was centrifuged at 100 x g for 3 mins using an Allegra® X-15R benchtop centrifuge 
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(Beckman Coulter, CA, USA) to get rid of the insoluble particulate. The three-way 
stopcock was directed from idle port to the column, where the syringe containing the 
sample solution was introduced. The sample was loaded onto the column at a flow rate 
of 1 mL/min.  
After loading the sample solution onto the column, the stopcock direction was 
changed to direct the flow of water towards the column. A flow rate of 1 mL/min was 
maintained while the sample was running in the column. Forty 10 mL fractions were 
collected and filter sterilized using a 0.2 μm filter (Sarstedt, Nümbrecht, Germany). The 
filter sterilized fractions were then lyophilized using FREEZONE freeze dryer 
(Labconco, MO, USA) at -52°C and 0.02 Torr, for 3 days, and stored at 4°C. After each 
use, the column was washed with five-bed volumes of water at 1.5 mL/min flow rate. 
This ensures the reusability of the resin present in the column. 
3.2.4 Assessing post-sephadex™ LH-20 fractions for bio-activity  
Determination of anti-proliferative activity of the post-Sephadex™ LH-20 fractions 
from Paxillus obscurisporus was done using MTT assay. To assess the anti-proliferative 
activity on various cancer cell lines, both time-dependent and dose-dependent MTT 
assays were performed. The cancer cell lines used were: SKOV3 (ovarian cancer cells), 
HCT116 (colon cancer cells), H441 (lung cancer cells), MCF7 (breast cancer cells) and 
HepG2 (human liver carcinoma). 
The protocol used for the MTT assay has been previously described in section 
2.3.1 of Chapter 2. Whereas, the immuno-stimulatory activity of Paxillus obscurisporus 
was confirmed by performing the Sandwich ELISA assay. The protocol used for 
sandwich ELISA has been described in section 2.3.2 of Chapter 2.  
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3.2.5 Assessment of carbohydrate content in bio-active fractions 
A Total Carbohydrate Assay Kit (Sigma-Aldrich®, St. Louis, MO, USA) was used to 
determine the presence of carbohydrates in the bio-active post-Sephadex™ LH-20 
fractions. The lyophilized post-Sephadex™ LH-20 fractions were re-suspended in water 
to make final concentration of 1 mg/mL. A 96-well plate was used to perform the assay. 
The carbohydrate standard provided with the kit was used as per the protocol at the 
concentrations: 0 mg/mL, 4 mg/mL, 8 mg/mL, 12 mg/mL, 16 mg/mL, and 20 mg/mL. 
The fractions (30 µL each) and the prepared standard dilutions were added to the 96-
well plate. To each well, 150 µL of sulphuric acid (12 M) was added and the 96-well 
plate was then incubated at 90°C using Haratherm™ General Oven (Thermo Fischer, 
Waltham, MA, USA) for 15 mins. After the incubation, 30 μL of developer was added to 
each well. The plate was then subjected for absorbance reading at 490 nm using 
SYNERGY 2 (BioTek®, VT, USA).     
3.3  Methodology – Purification by means of anion-exchange chromatography 
using DEAE Sephadex™  
The DEAE Sephadex™ (GE Healthcare, Quebec) is an anion-exchanger that is 
based on Sephadex crossed-linked dextran matrix. Sephadex is widely used in plasma 
fractionation and other separation processes based on ionic charge of a sample. 
Various buffer systems supported by the DEAE Sephadex™, which were mentioned in 
the user manual, were used (table 3.1). For preparation of the medium, the dry 
powdered DEAE Sephadex™ was weighed and mixed with the buffer system, and left 
to swell for about 48 hours. Later, the swollen DEAE Sephadex™ was introduced to a 
column, where 3 parts were swollen DEAE Sephadex™ and one part was the buffer. 
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Table 3.1: Buffers used in the anion-exchange DEAE Sephadex™ column 
chromatography. 
Buffer pH Range Concentration 
N-Methyl Piperazine 4.3-5.3 20mM 
Piperazine 4.8-5.8 20mM 
TRIS 7.6-8.6 20mM 
Diethanolamine 8.4-9.4 20mM 
 
3.3.1 Purification through anion-exchange chromatography using Poly-
Prep® chromatography columns 
 For anion-exchange chromatography, Poly-Prep® chromatography columns with a 
maximum capacity of 12 mL were used. The column was loaded with a 2 mL slurry that 
contained 75% swollen resin and 25% buffer, forming the final bed volume. The column 
was washed with three to five bed volumes of buffer to equilibrate the column at the 
buffer’s pH. After the wash, the lyophilized anti-proliferative post-Sephadex™ LH-20 
fractions from Paxillus obscurisporus were suspended in the running buffer at the 
concentration of 0.5 mg/mL. The post-Sephadex™ LH-20 fractions suspended in buffer 
were loaded onto the column and allowed to pass through the column by means of 
gravity. The column was flushed with the running buffer to attain the “flow-through”. A 
total of three flow-through fractions were collected; each of the 3 fractions had the same 
volume of 2 mL. 
The flow-through obtained was subjected to 48 hour MTT assays to assess whether 
the bio-active compounds were bound to the DEAE Sephadex™ at any of the buffers 
tested. A 25 μL volume of start buffer was used as the negative control. Twenty-five μL 
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of post-Sephadex™ LH-20 fraction reconstituted in the buffer at 0.5 mg/mL was used as 
a positive control. Twenty-five μL of flow-through was used as a sample. The positive 
control, negative control and samples were added to HeLa cells consisting 175 μL 
EMEM containing 10% fetal bovine serum. 
3.3.2 Purification using 140mL DEAE Sephadex™ on a C16/70 column 
To attain higher yield of purified anti-proliferative compounds from Paxillus 
obscurisporus, a larger C16/70 column (GE Healthcare, Quebec) having a total volume 
of 140 mL was used. About 19 g of dry DEAE Sephadex™ was swollen for about 48 
hours using approximately 120 mL of degassed 20mM piperazine buffer with pH 5.5. An 
AC 16 (GE Healthcare, Quebec) flow adapter, which maintains the pressure, flow rate, 
and prevents the backflow of the buffer, was placed at the bottom of the column. The 
swollen resin was loaded on the column using a RC 16 (GE Healthcare, Quebec) 
reservoir and allowed to settle in the column. Once the swollen resin was settled in the 
column, the packing was done by placing another AC 16 adapter on the top-end of the 
column. The tubing attached to the AC 16 flow adapter was connected to the P-50 
pump (Pharmacia Biotech, Sweden) that maintained the buffer flow rate. While packing 
the column, the flow rate was maintained at 2 mL/min. A three-way stopcock was used 
so that while the samples were loaded onto the column, the pump could be stopped. 
About 10 mL sample solution having a concentration of 40 mg/mL was prepared 
using the lyophilized bio-active anti-proliferative fractions from Paxillus obscurisporus in 
20 mM piperazine, pH 5.5. The three-way stopcock was directed from idle port to the 
column, where the syringe containing the sample solution was introduced. The sample 
was loaded onto the column at a flow rate of 1 mL/min.  
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After loading the sample solution onto the column, the stopcock direction was 
changed so that the flow of the buffer from the pump could be directed to the column. A 
flow rate of 1 mL/min was maintained while the sample was loaded onto the column. 
Twenty-five 12 mL flow-through fractions were collected and lyophilized using 
FREEZONE freeze dryer (Labconco, MO, USA) at -52°C and 0.02 Torr, for 24 hours. 
The lyophilized flow-through was then suspended in water and dialyzed using Slide-A-
Lyzer™ dialysis cassette (Thermo Fischer Scientific, MA, USA) with a molecular size 
cut-off (MWCO) of 2,000 Da. The dialysis eliminated the presence of the buffer 
components in the flow-through. The dialyzed flow-through was then filter-sterilized 
using 0.2 µm filters (Sarstedt, Nümbrecht, Germany) and stored at 4°C.   
3.3.3 Assessment of anti-proliferative activity of post-DEAE Sephadex™ 
flow-through 
The determination of the anti-proliferative activity of the post-DEAE Sephadex™ 
flow-through from Paxillus obscurisporus was performed using MTT assay. The anti-
proliferative activity of the flow-through obtained was observed. A loss in anti-
proliferative activity would suggest binding of the bio-active anti-proliferative compounds 
with DEAE Sephadex™. The protocol used for MTT assay was described in section 
2.3.1 of Chapter 2. 
3.3.4 Assessment of presence of protein and glycoprotein in post-DEAE 
Sephadex™ flow-through   
Results of the anti-proliferative activity assessment of post-DEAE Sephadex™ flow-
through fractions mentioned in section 3.4.8 suggested that the bio-active compounds 
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were present in the flow-through. This was the reason that only the flow-through 
fractions collected were assessed for the presence of protein and glycoprotein.  
SDS-PAGE coomassie blue (loading dye) stain was used to stain any proteins 
present in the post-DEAE Sephadex™ flow-through. The PagerRuler™ Plus (Thermo 
Fischer Scientific, Waltham, MA, USA) pre-stained protein ladder having a range of 10 
kDa to 250 kDa was used as a standard marker. A 12% SDS-PAGE gel was loaded 
with 30 μL post-DEAE Sephadex™ flow-throughs at 5 mg/mL along with the protein 
ladder. The gel was placed in the running buffer and a 200 V electrical current was 
applied.  
To assess the presence of any glycoprotein and its size, the same procedure was 
followed as above. Pierce Glycoprotein Staining Kit (Thermo Fischer Scientific, 
Waltham, MA, USA) was used. For staining the post-DEAE Sephadex™ flow-through, 
the electrophoresis of the gel was done by the same procedure as mentioned above for 
protein staining. After the electrophoresis, the gel was fixed by completely immersing it 
in 100 mL of 50% methanol for 30 mins. The gel was then washed by gently agitating 
with 100 mL of 3% acetic acid for 10 minutes. The wash step was repeated twice. After 
the wash, the gel was transferred to 25 mL of the oxidizing solution and gently agitated 
for 15 mins. The gel was then again washed by gently agitating with 3% acetic acid for 5 
mins. The wash step was repeated for two more times. After the wash step, the gel was 
transferred to 25 mL of glycoprotein staining reagent and gently agitated for 15 mins. 
The gel was then transferred to 25 mL of reducing solution and gently agitated for 5 
mins. After treatment with the reducing solution, the gel was washed extensively with 
3% acetic acid and then with ultrapure water. After the gels for protein and glycoprotein 
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were subjected to electrophoresis and stained as described as above, images of gels 
were taken using Fluorchem imager trans-illuminator to take pictures. The SDS gel 
staining experiments described above were performed entirely by Dr. Wai Ming Li and 
Ms. Sumreen Javed. 
3.4  Results and Discussion  
3.4.1 DNA identification of the collected Paxillus obscurisporus  
New specimens of Paxillus obscurisporus were collected by Dr. Hugues 
Massicotte and Dr. Zoë Meletis in June 2015. The fruiting bodies of Paxillus 
obscurisporus were cleaned and dried at 55°C using a dryer. The dried fruiting bodies 
were then ground to powder using a conventional food processor. The powder obtained 
from the fruiting bodies was subjected to DNA identification using ITS2 and NLB4 
primers. The morphological description and the DNA identification results are below: 
Morphological Characteristics: 
Type:   Gilled mushroom fruiting body 
Size:   Cap – 4-16cms, Stem – 2-5cms long and 0.4-3cms wide. 
Color:   Cap – dark brown, Stem – dark cream - brown, Gills - cream 
Gills:  Close, crowded and forking 
Spore Deposit: Brown to yellow brown  
Flesh:  Thick and firm  
Habitat:   Found densely populated on ground and woods  
Matchmaker Mushroom match: Paxillus obscurisporus/Paxillus involutus 
Sequencing match:  Paxillus obscurisporus (C.Hahn, 1999) 
 
Primer used:  NLB4 and ITS3 
Max score:   213  
Total score:   213 
Query covered:   21% 
Identification:   98% 
Accession:  KF261386.1 
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 The DNA sequence obtained is shown in the Appendix iii. As seen in the DNA 
sequencing results summarized above, the query covered by the DNA sequence 
obtained from the mushroom was only 21%. This indicated that there was only a 21% 
match between the sample DNA sequence and the matched DNA sequence from the 
GenBank from the NIH database. Also, the quality of the DNA sequence obtained was 
poor. This could be because of cross-contamination of samples from related species 
occurring in the same area from where Paxillus obscurisporus was obtained or fungi 
growing parasitically on the fruiting bodies.  
3.4.2 Bio-activity of Paxillus obscurisporus collected in 2015 
As seen in figure 3.1(A), the 5% NaOH extract reduced the cell viability to 60% at 
1 mg/mL. As compared to the anti-proliferative activity from the previous specimens 
(collected in 2013), the 5% NaOH extract of Paxillus obscurisporus collected in 2015 did 
not seem to possess activity at a lower concentration. The previous batch of Paxillus 
obscurisporus (2013) reduced the cell viability to 40% at 0.2 mg/mL. Conversely, the 
5% NaOH extract from 2015 shows a gradual decrease in cell viability with increasing 
dose. 
Figure 3.1(B) shows that 1 mg/mL of 5% NaOH extract from Paxillus 
obscurisporus (2015) induced TNF-α to about 3,260 pg/mL after a 6-hour treatment on 
RAW264.7 cells. As compared to the immuno-stimulatory activity of the 5% NaOH 
extract from Paxillus obscurisporus collected in 2013, there was a reduction of 
approximately 1,000 pg/mL of TNF-α.   
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Figure 3.1: Result of anti-proliferative MTT and immuno-stimulatory ELISA assay of 
NaOH extract from P. obscurisporus: (A) the anti-proliferative dose-dependent MTT assay of 
5% NaOH extract from Paxillus obscurisporus, where water was used as a negative control, (B) 
immuno-stimulatory ELISA assay where RAW264.7 cells were treated with 1 mg/mL of 5% 
NaOH extract. Water was used as a negative control and LPS was used as a positive control. 
Error bars are standard deviation.   
Although the newer batch of Paxillus obscurisporus showed reduced bio-activity, 
it was used for further purification and chemical characterization. The fruiting bodies of 
Paxillus obscurisporus obtained in 2015 were generally smaller, indicating that the 
fruiting bodies collected were less mature perhaps. The fruiting bodies of Paxillus 
obscurisporus obtained in 2013 were twice as large compared to the ones from 2015. 
This might indicate that the younger and less mature fruiting bodies of Paxillus 
obscurisporus might possess less of the compounds that are responsible for the anti-
proliferative activity.     
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3.4.3 Bio-activity of post-Sephadex™ LH-20 fractions from a 16 mL drip 
column 
Results from the 48 hour MTT assay performed on the post-Sephadex™ LH-20   
fractions obtained from the 5% NaOH extract of Paxillus obscurisporus are shown in 
Figure 3.2. Results showed that fractions five and six reduced the HeLa cell viability by 
70% and 50% respectively. The total bed volume of the column was 16 mL. The fraction 
size collected was 1.5 mL. This suggested that the anti-proliferative fractions five and 
six falls roughly on the 50% and 60% of total bed volume. The void volume is defined as 
the volume of mobile phase (buffer) passing through the gel required to elute the 
molecule(s) that never entered the stationary phase. The void volume for Sephadex™ 
LH-20 is roughly between 30-40% of the total bed volume as mentioned in the user 
manual provided by the manufacturer. This means that the bio-active fractions could be 
in the inclusion volume that falls in the range of the Sephadex™ LH-20 that is 100-4,000 
Da (depending on molecular shape of compounds). Whereas, if the bio-active 
compound(s) are not in the inclusion limit (fraction 1-7), which constitutes 0-40% of bed 
volume, it would suggest that the bio-active molecule(s) are higher than 4,000 Da 
molecular weight.     
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Figure 3.2: Results of MTT assay of post-Sephadex™ LH-20 fraction from 5% NaOH 
extract of P. obscurisporus: Effect of 100μL of post-Sephadex™ LH-20 fraction on HeLa cells 
viability. Cells were treated with fractions for 48 hours. Water was used as the negative control. 
The graph is representative results from two different replicate (n=2). Error bars are average. 
 Results from the immuno-stimulatory ELISA assay performed on the post-
Sephadex™ LH-20 fractions obtained from 5% NaOH extract of Paxillus obscurisporus 
are shown in Figure 3.3. Results showed that water used as a negative control had very 
minimal or no effect. Fractions 8 to 17 showed no immuno-stimulatory activity. Fraction 
4 was most active, inducing TNF-α to approximately 650 pg/mL and the immuno-
stimulatory activity gradually falls from fractions 4 to 8.  
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Figure 3.3: Results of Immuno-stimulatory ELISA assay of post-Sephadex™ LH-20 
fraction from the NaOH extract of P. obscurisporus: TNF-alpha production in Raw 264.7 
cells upon treatment with 100 μL of fractions for 6 hours. LPS was used as a positive control 
and water was used as a negative control. Error bars are average. 
3.4.4 Bio-activity of post-Sephadex™ LH-20 fractions from 120mL C16/70 
column 
After successful separation of the anti-proliferative and the immuno-stimulatory 
compounds attained through 16 mL column, the purification was scaled up using a 
larger C 16/70 (120 mL) column. Figure 3.4 (A) shows that fractions 6 and 7 obtained 
from the C 16/70 column, which had a bed volume of 120 mL, reduced HeLa cell 
viability by 90% and exhibits strong anti-proliferative activity. The elution pattern 
occurring in the larger C 16/70 column differed from the elution pattern of the smaller 16 
mL column. Anti-proliferative fractions 6 and 7 fell in-between 34% to 47% of elution 
volume and may be in the inclusion limit. Although the active anti-proliferative 
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compounds were just occurring in the beginning of inclusion volume, they seemed to fall 
in Sephadex™ LH-20 operative/inclusion range.     
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Figure 3.4: Results of MTT and ELISA assay of post-Sephadex™ LH-20 fractions from 
NaOH extract of P. obscurisporus: (A) Effect of 100 μL of post-Sephadex™ LH-20 fraction on 
HeLa cells viability. Water was used as the negative control. The graph is representative results 
from two different replicate (n=2). Error bars are average. (B) TNF-alpha production in Raw  
264.7 cells upon treatment with 100 μL of fractions for 6 hours. LPS was used as the positive 
control and water was used as the negative control. The graph is representative results from 
two different replicate (n=2). Error bars are standard deviation. 
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 The result of the immuno-stimulatory ELISA assay performed on the post-
Sephadex™ LH-20 fractions obtained from 5% NaOH extract of Paxillus obscurisporus 
is shown in Figure 3.4(B). The result shows strong immuno-stimulation by fraction 8, 9, 
10 and 11. The fractions eluting after fraction 9 showed gradual decrease in TNF-α 
production. Comparing the results of anti-proliferative MTT assay and immuno-
stimulatory ELISA assay, it is evident that there was a clear separation of active anti-
proliferative compounds (occurring in fractions 6 and 7) from active immuno-stimulatory 
fractions (occurring from fractions 8 to 17). RAW 264.7 cells were observed under the 
microscope after 6 hours of treatment with post-Sephadex™ LH-20 fractions and just 
before obtaining the supernatant, and there were no signs of cell death from any of the 
fractions.  
To obtain large amounts of purified compounds from gel-permeation/size-
exclusion chromatography, the C 16/70 column was run 6 times. Fractions obtained 
from each of the purification column were analyzed using MTT assay to confirm the 
reproducibility of the anti-proliferative activity. The trend of elution remained the same 
where the bio-active anti-proliferative compounds were eluted in fractions 6 and 7. Both 
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fractions 6 and 7 were dark yellow to brown in colour.  
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Figure 3.5: Results of MTT assay of post-Sephadex™ LH-20 (C16/70 column) fractions 
from NaOH extract of P. obscurisporus: (A) Effect of 100 μL of post-Sephadex™ LH-20 
fractions (obtained from the 3rd C16/70 column elution) on HeLa cells viability. Water was used 
as the negative control. The graph is representative results from two different replicate (n=2). 
(B) Effect of 100 μL of post-Sephadex™ LH-20 fractions on HeLa cells where the fractions were 
obtained from 5th C 16/70 column elution. The flow rate was at 0.5 mL/min. and 2.5 mL fractions 
were collected. Water was used as the negative control. The graph is representative results 
from four different replicate (n=4). Error bars are average. 
As shown in Figure 3.5 (A), fractions 6 and 7 obtained from the 3rd C 16/70 
column elution had strong anti-proliferative activity, confirming the reproducibility 
between various columns. To attain a better resolution of separation/purification, the 
flow rate was reduced to 0.5 mL/min and fraction size was reduced to 2.5 mL in the 5th 
C 16/70 column elution. The result shown in Figure 3.5(B) indicated that the active anti-
proliferative compounds were concentrated in between fractions 6-2, 6-3, and 7-1. 
Since there was no weak activity in between these sub-fractions, it may be assumed 
that these fractions could contain molecules of similar chemical nature. Figure 3.5 also 
indicates the reproducibility of the elution pattern between various columns. 
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3.4.5 Bio-activity of post-Sephadex™ LH-20 fractions using a 500 mL C 
26/100 column 
To obtain larger amounts of purified anti-proliferative compounds from 5% NaOH 
extract of Paxillus obscurisporus, the C 26/100 column (GE Healthcare, Quebec) was 
used. The total bed volume of this column was approximately 500 mL. The total amount 
of sample loaded was 400 mg (10 mL) of 5% NaOH extract of Paxillus obscurisporus. 
The results from the 48 hours MTT assays are shown in Figure 3.6(A). The result 
suggests that fractions 17-24 showed strong anti-proliferative activity. Whereas, Figure 
3.6(B) showed that fractions 25-35 exhibited immuno-stimulation by inducing TNF-α. 
Fractions 28 and 29 showed strong immuno-stimulation by inducing TNF-α to 
approximately 2,700 pg/mL. The fractions eluting after fraction 28 showed gradual 
decrease in immuno-stimulation.  
The elution volume at which the active anti-proliferative fractions (140-240 mL) 
was occurring in between 34-47% of the total bed volume. This elution pattern was 
similar to the elution pattern of the smaller C 16/70 column. Here again, a clear 
separation can be seen between active anti-proliferative fractions 17-24 and active 
immuno-stimulatory fractions 25-35, indicating two separate classes of biomolecules. 
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Figure 3.6: Results of MTT and ELISA assay of post-Sephadex™ LH-20 (C26/100) 
fractions from NaOH extract of P. obscurisporus: (A) Effect of 100 μL of post-Sephadex™ 
LH-20 fractions on HeLa cell viability. Water was used as the negative control. The graph is 
representative results from four different replicate (n=4). Error bars are average. (B) TNF-α 
production in Raw  264.7 cells upon treatment with 100 μL of fractions for 6 hours. LPS was 
used as the positive control and water was used as the negative control. Error bars are standard 
deviation.  
 To confirm the reproducibility of the elution pattern of bio-active fractions on C 
26/100 column, the 48 hours MTT assay and immuno-stimulatory ELISA assay were 
performed on each column eluted with 5% NaOH extract of Paxillus obscurisporus. It 
was evident that the elution pattern was very reproducible and the active anti-
proliferative compounds were eluting out in the same region, in between 35-50% of total 
bed volume, whereas the active immuno-stimulatory compounds were eluting out just 
after 50% with earlier fractions, being more potent than the latter. Figure 3.7 (A and B) 
shows that the elution pattern for the active anti-proliferative and immuno-stimulatory 
compounds from 5% NaOH extract of Paxillus obscurisporus of column chromatography 
no. 4 was identical to the previous column runs. This shows that the replicated column 
chromatography performed on 5% NaOH extract of Paxillus obscurisporus had a very 
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consistent elution pattern for active anti-proliferative and immuno-stimulatory 
compounds.  
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Figure 3.7: Results of MTT and ELISA assay of post-Sephadex™ LH-20 (C26/100) 
fractions from NaOH extract of P. obscurisporus: (A) Effect of 100 μL of post-Sephadex™ 
LH-20 fractions on HeLa cell viability. Water was used as the negative control. The graph is 
representative results from four different replicate (n=4). (B) TNF-α production in Raw  264.7 
cells upon treatment with 100 μL of fractions for 6 hours. LPS was used as the positive control 
and water was used as the negative control. Error bars are standard deviation. 
 After a consistent elution pattern was confirmed, the column chromatography 
was performed with C 26/100 Sephadex™ LH-20 for a total of 8 times to collect large 
amounts of active anti-proliferative compounds to perform further purification. Fractions 
16-23 were pooled together, filter sterilized, lyophilized, and stored at 4°C for further 
analysis.  
3.4.6 Effect of bio-activity of post-Sephadex™ LH-20 fractions on various 
cell lines 
As shown in Figure 3.8, the post C2 6/100 column fraction showed little anti-
proliferative activity at 0.01 mg/mL and the anti-proliferative activity was strongest at 0.5 
68 
 
 
mg/mL, where the cell viability was reduced to 40% in HepG2 and H441 cells. Whereas, 
the cell viability was reduced to approximately 20% in both HeLa and HCT116 cells at 
0.5 mg/mL of the post-Sephadex™ LH-20 bio-active fraction.  
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Figure 3.8: Results of 48 hours MTT dose-dependent assay performed using post-
Sephadex™ LH-20 fractions from 5% NaOH extract of P. obscurisporus on (A) HCT-116 
(colorectal carcinoma) cells, (B) HeLa (cervical cancer) cells, (C) HepG2 (human liver 
carcinoma) cells and (D) H441 (human papillary adenocarcinoma) cells were treated with 
various concentration of post-Sephadex™ LH-20 fractions. Each graph is a representative result 
from two different replicate (n=2). Error bars are standard deviation.      
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Figure 3.9: Results of 48 hours MTT dose-dependent assay performed using post-
Sephadex™ LH-20 fractions from 5% NaOH extract of P. obscurisporus. (A) MCF7 (human 
breast adenocarcinoma) cells, (B) SKOV3 (human ovarian adenocarcinoma) cells, (C) U251 
(human glioblastoma) cells, and (D) U87 (human glioblastoma) cells were treated with various 
concentration of post-Sephadex™ LH-20 fraction. Error bars are standard deviation. 
 Further results from the dose-dependent MTT assays are shown in Figure 3.9. 
Results indicated a gradual reduction in cell viability with increasing dose of post C 
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26/100 column fractions from 5% NaOH extract of Paxillus obscurisporus. At 0.5 
mg/mL, the post-Sephadex™ LH-20 fraction reduced the cell viability to about 15% in 
U251 and U87 (human glioblastoma cells) as well as in MCF-7 (human breast 
adenocarcinoma) cells. The cell viability was reduced to 30% in SKOV3 (human ovarian 
adenocarcinoma) cells. An MTT assay using U87 and U251 cells was performed by 
fellow project member Mr. Faran Rashid.  
 As seen in the dose-dependent MTT assay on various cell lines, it is evident that 
the post-Sephadex™ LH-20 fraction showed strong anti-proliferation at 0.5 mg/mL in all 
the cell lines. Time- dependent MTT assay was next performed using 0.5 mg/mL of 
post-Sephadex™ LH-20 fractions. Results from the time-dependent experiments are 
shown in Figure 3.10 (A and B). These results showed that the post-Sephadex™ LH-20 
fraction reduced the cell viability to about 7% at 48 hours in both HCT116 and HeLa 
cells. The cell viability remained at approximately 7% till 120 hours. At the 24-hour time 
point, there was an increase in cell viability to 30% in HCT116 cells.  
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Figure 3.10: MTT time-dependent assay performed using post-Sephadex™ LH-20 
fractions from 5% NaOH extract (0.5mg/mL) of P. obscurisporus. (A) HCT-116 (colorectal 
carcinoma) cells and (B) HeLa (cervical cancer) cells were treated with 0.5 mg/mL of post-
Sephadex™ LH-20 fraction. Error bars are standard deviation. 
 Further results from the time-dependent MTT assays are shown in Figure 3.11. 
The results showed that the cell viability of HepG2 and H441 cells were reduced to 15% 
at 120 hours whereas the cell viability of MCF-7 and SKOV3 cells was reduced to 
approximately 20% at 48 hours. The cell viability was eventually reduced to about 10% 
at 120 hours. Water was used as a negative control in the time-dependent MTT assay, 
as the post-Sephadex™ LH-20 fractions were re-suspended in water. 
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Figure 3.11: MTT time-dependent assay performed using post-Sephadex™ LH-20 
fractions from 5% NaOH extract (0.5mg/mL) of P. obscurisporus. (A) HepG2 (human liver 
carcinoma) cells, (B) H441 (human papillary adenocarcinoma) cells, (C) MCF-7 (human breast 
adenocarcinoma) cells, and (D) SKOV3 (human ovarian adenocarcinoma) were treated with 0.5 
mg/mL of post-Sephadex™ LH-20 fraction. Error bars are standard deviation. 
 It was observed from Figure 3.10 (A), 3.11 (A) and (B) that, at the 24 h time 
point, there was an increase in cell viability. The results suggested that the bio-active 
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molecules that are present in the Sephadex™ LH-20 fractions required a timeframe of 
about 48 hours to act on the cell to produce an anti-proliferative effect.  
3.4.7 Carbohydrate content in bio-active fractions 
The post-Sephadex™ LH-20 fractions obtained from the C 16/70 columns were 
subjected to total carbohydrate assay using a Total Carbohydrate Assay Kit (Sigma-
Aldrich®, St. Louis, MO, USA). The result from this assay is shown in Figure 3.12. The 
result suggested presence of about 366 μg/mL and 220 μg/mL of carbohydrate 
compound(s) in Fractions 6 and 7 respectively. This suggests that the anti-proliferative 
fractions contain carbohydrate molecules, which may be a component of the active 
compounds. The carbohydrate molecules remain at a lower concentration in Fractions 8 
and 10 (approximately 80 μg/mL) and increases in fractions 10 and 11.  
 
Figure 3.12: Total carbohydrate assay of post-Sephadex LH-20 fractions from C 16/70 
column.  
 Result from this experiment confirms the presence of carbohydrates in bio-active 
anti-proliferative fractions. Although carbohydrate molecules are present in few immuno-
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stimulatory fractions (Fraction 8, 9, 10 and 11), the quantity seems to be lower than that 
of the anti-proliferative fractions. This may suggest the presence of a mixture of 
polysaccharides in the bio-active fractions, which may be inter-related structurally. This 
further supports the notion that the anti-proliferative and immuno-stimulatory fractions 
are separate and distinct molecules. 
3.4.8 DEAE Sephadex™ anion-exchange chromatography using mini Poly-
Prep® chromatography columns 
  The pooled bio-active fractions from LH20-Sephadex were run through the 
DEAE-Sephadex column. The flow-through obtained from DEAE Sephadex™ was 
analyzed for anti-proliferative activity using MTT assay. The anti-proliferative activity of 
the flow-through obtained was assessed through performing MTT assay. A loss in anti-
proliferative activity would suggest binding of the bio-active anti-proliferative compounds 
with DEAE Sephadex™. Figure 3.13 suggested that there was no binding of bio-active 
anti-proliferative compounds with the DEAE Sephadex™ when 20 mM of 1-methyl-
piperazine (pH 4.5) and 20 mM piperazine (pH 5.5) were used as buffers, as the flow-
through showed anti-proliferative activity. Figure 3.13 (A) shows that the preload (post-
Sephadex™ LH-20 fraction resuspended in 20 mM 1-methyl-piperazine at 0.5 mg/mL) 
reduced the cell viability to 60%, indicating a loss in anti-proliferative activity when 
compared to the 0.5 mg/mL post-Sephadex™ LH-20 fraction serving as the positive 
control. Flow-through 1 and 2 reduced the cell viability to approximately 80%, 
suggesting some degree of binding of bio-active anti-proliferative compounds to the 
DEAE Sephadex™. But the preload itself showed weak activity, which suggested that 
the buffer used (1-methyl-piperazine) may somehow reduce the activity of the bio-active 
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compound(s). The loss in activity could be the result of protonation of the bio-active 
compound at lower pH (4.5).  
Figure 3.13(B) shows that the preload (post-Sephadex™ LH-20 fraction 
resuspended in 20 mM piperazine pH 5.5 at 05 mg/mL) reduced the cell viability to 
approximately 7%. On the other hand, flow-through 1 and 2 reduced the cell viability to 
30% and 45% respectively. Flow-through 3 was unable to reduce the cell viability. This 
suggested that there was no binding of the bio-active compounds with the DEAE 
Sephadex™. 
0
20
40
60
80
100
120
140
A. 48Hrs. MTT Assay 
C
el
l V
ia
bi
lit
y 
(%
 C
on
tr
ol
)
C
on
tr
ol
P
re
lo
ad
 
(0
.5
m
g/
m
l) Fl
o
w
th
ro
ug
h-
1
Fl
o
w
th
ro
ug
h-
2
Fl
o
w
th
ro
ug
h 
3
0
20
40
60
80
100
120
140
B. 48Hrs. MTT Assay
C
el
l V
ia
bi
lit
y 
(%
 C
on
tr
ol
)
C
on
tr
ol
P
re
lo
ad
 
(0
.5
m
g/
m
l)
Fl
ow
th
ro
ug
h-
1
Fl
ow
th
ro
ug
h-
2
Fl
ow
th
ro
ug
h-
3
 
Figure 3.13: MTT assay performed on post-DEAE Sephadex flow-through: (A) 25 μL of 
flow-through obtained using 1-methyl-piperazine pH 4.5 buffer was added to HeLa cells, where 
25 μL of buffer was used as a negative control, 25 μL post-Sephadex™ LH-20 fraction 
reconstituted in buffer (preload) at 0.5 mg/mL was used as a positive control, (B) 25 μL of flow-
through obtained using piperazine pH5.5 as buffer, 25 μL of buffer was used as a negative 
control, 25 μL post-Sephadex™ LH-20 fraction reconstituted in buffer (preload) at 0.5 mg/mL 
was used as a positive control and 25μL of flow-through was the sample. Error bars are 
standard deviation.    
 Figure 3.14(A) shows that the flow-through obtained using 20 mM Tris buffer at 
pH 7.4 had anti-proliferative activity; where flow-through 1 reduced the cell viability to 
40%, flow-through 2 reduced the cell viability to 55% and flow-through 3 reduced the 
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cell viability to 67%. The preload (post-Sephadex™ LH-20 fraction was resuspended in 
20 mM Tris pH 7.4) had potent anti-proliferative activity, reducing the cell viability to 5%. 
This result suggests that there is no or weak binding between the active anti-
proliferative compounds and the anion-exchange medium, as the flow-through showed 
relatively strong anti-proliferative activity. 
 Figure 3.14(B) shows that the flow-through 1, 2, and 3 obtained using 
diethanolamine pH 8.4 as a buffer; each flow-through showed anti-proliferative activity 
suggesting that there was little or no binding between active anti-proliferative 
compounds and the anion-exchange resin. Flow-through 1 reduced the cell viability to 
60%, flow-through 2 reduced the cell viability to 80% and flow-through 3 reduced the 
cell viability to 77%. The preload (post-Sephadex™ LH-20 fraction re-suspended in 
buffer at 0.5 mg/mL) included as a positive control reduced the cell viability to 9%.  
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Figure 3.14: MTT assay performed on post-DEAE Sephadex™ flow-through: (A) 25 μL of 
flow-through obtained using 20 mM Tris pH 7.4 buffer was added to HeLa cells, where 25 μL of 
buffer was used as a negative control and 25 μL post-Sephadex™ LH-20 fraction reconstituted 
in buffer (Preload) at 0.5 mg/mL was used as a positive control, (B) 25 μL of flow-through 
obtained using 20 mM diethanolamine pH 8.4 as buffer, 25 μL of buffer was used as a negative 
control, 25 μL post-Sephadex™ LH-20 fraction reconstituted in buffer (Preload) at 0.5 mg/mL 
was used as a positive control and 25 μL of flow-through was the sample. Error bars are 
standard deviation.    
 Overall, the results from the DEAE Sephadex™ suggest that there was very little 
binding between the active anti-proliferative post-Sephadex™ LH-20 fractions and the 
DEAE Sephadex™ anion-exchange resin. After the flow-through was obtained from the 
column where 20 mM piperazine was used, the colored pigment in the fraction 
appeared to be retained by the column (Figure 3.15B). The flow-through obtained from 
this column under the conditions used was colourless. This suggests that the coloured 
pigment was interacting with the anion-exchange resin and likely binding to it. 
 Since there was no strong binding between the anion-exchange resin and the 
bio-active compound(s), and there was indication of removal of unwanted coloured 
compound(s) bound to DEAE Sephadex™, it was deemed logical to collect the flow-
79 
 
 
through from the DEAE Sephadex™ as a mean to purify the bio-active anti-proliferative 
compound(s). 
 To confirm the reproducibility of the DEAE Sephadex™ anion-exchange 
chromatography using 20 mM piperazine pH 5.5, a 2 mL and 5 mL drip column were 
run simultaneously under the same conditions. The flow-through obtained from these 
columns was dialyzed, lyophilized and tested for anti-proliferative activity. The flow-
through was dialyzed to remove the buffer component piperazine. 
The results from the MTT assay are shown in Figure 3.15(A). The results show 
that the flow-through obtained from the 2 mL anion-exchange column reduced the cell 
viability to 40% and the flow-through obtained from the 5 mL anion-exchange column 
reduced the cell viability to 6%. This showed the reproducibility of the conditions in 
which separation occurred. The low anti-proliferative activity from flow-through obtained 
from the 2 mL column could be attributed to the over saturation of the anion-exchange 
medium; this occurs when the sample to be analysed has a higher ionic strength than 2 
mmol/g of dry powder. Since the post-Sephadex™ LH-20 fractions from Paxillus 
obscurisporus was a mixture of various compounds, the ionic strength of the 
compound(s) was unknown. This may have caused the saturation of the anion-
exchange resin, leading to occurrence of non-anti-proliferative compounds in the flow-
through and reduced its activity. So, when the total bed volume of the column was 
increased to 5 mL, the flow-through obtained from the same sample at the same 
strength showed higher anti-proliferative activity, reducing the cell viability to 6%. 
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Figure 3.15: (A) MTT assay performed on post-DEAE Sephadex™ flow-through: flow-
through obtained using 20 mM piperazine pH 5.5 buffer using 2 mL and 5 mL column were 
added to HeLa cells. Water was used as a negative control and post-Sephadex™ LH-20 
fraction reconstituted in buffer labelled as “Preload” was used as a positive control at the 
concentration of 0.5 mg/mL. Error bars are standard deviation. (B) Binding of coloured pigment 
in the post-Sephadex™ LH-20 fraction with DEAE Sephadex™ after the flow-through was 
collected. 
3.4.9 DEAE Sephadex™ anion-exchange chromatography using C 16/70 
columns 
Since the efficiency and reproducibility of the anion-exchange chromatography 
performed using 20 mM piperazine at pH 5.5 was assessed, this experiment was scaled 
up using a larger C 16/70 column under the same conditions. The result is shown in 
Figure 3.16. The result showed that the purified flow-through reduced the cell viability to 
5% at 0.5 mg/mL, to 57% at 0.02 mg/mL, and to 64% at 0.002 mg/mL.    
B. 2mL Poly-Prep® column 
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Figure 3.16: MTT assay performed on post-DEAE Sephadex™ flow-through: (A) flow-
through obtained using 20 mM piperazine pH 5.5 buffer and 75 mL C 16/70 column was added 
to HeLa cells. Water was used as a negative control, and post-Sephadex™ LH-20 fraction 
reconstituted in buffer labeled as “Preload” was used as a positive control at the concentration 
of 0.5 mg/mL. Error bars are standard deviation.    
To observe the specific activity of the flow-through fractions obtained using 
DEAE Sephadex™, its anti-proliferative activity was compared to anti-proliferative 
activity of the fractions obtained through Sephadex™ LH-20. Figure 3.17 (A and B) 
shows the result of dose-dependent assays performed on post-DEAE Sephadex™ flow-
through fractions and post-Sephadex™ LH-20 respectively. Results show that the flow-
through fractions obtained from DEAE Sephadex™ inhibited the cell viability to 5% at 
0.5 mg/mL, to 57% at 0.02 mg/mL and to 64% at 0.002 mg/mL. Whereas, the post-
Sephadex™ LH-20 fraction reduced the cell viability to 73% at 0.01 mg/mL, to 51% at 
0.01 mg/mL and to 25% at 0.5 mg/mL. When compared, the anti-proliferative activity 
exhibited by post-DEAE Sephadex™ flow-through fractions was higher at lower doses 
than that of post-Sephadex™ LH-20 fractions. This was a clear indication that the 
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purification of post-Sephadex™ LH-20 fractions was successful when subjected to 
anion-exchange chromatography using DEAE Sephadex™. 
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Figure 3.17: Dose-dependent MTT assays performed using (A) post-Sephadex™ LH-20 
fractions and (B) post-DEAE Sephadex™ flow-through fractions on HeLa cells. Water was used 
as negative control. Error bars are standard deviation.  
3.4.10 Assessing the presence of proteins and glycoproteins in bio-active 
DEAE Sephadex™ fractions  
The experiments described in this section were performed entirely by Dr. Wai 
Ming Li and Ms. Sumreen Javed. To detect the possible presence of protein and 
glycoproteins in post-DEAE Sephadex™ flow-through from Paxillus obscurisporus, the 
samples were analyzed using SDS-PAGE gel staining with Coomassie blue for proteins 
components and other glycoprotein staining reagents for glycoprotein complexes 
Results of the SDS-PAGE experiments stained for the presence of protein and 
carbohydrate are shown in Figure 3.18 (A and B) respectively. The result for protein 
staining showed that Polysaccharide-K (PSK), which is the well know polysaccharide-
peptide isolated from the mushroom Trametes versicolor, exhibited a smearing pattern 
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weight of 44 kDa. A band for PSK acting as a positive control appears at 250 kDa with a 
smear extending from 35 kDa to 250 kDa. A faint band of post-DEAE fraction from 
Paxillus obscurisporus could be seen at 250 kDa, suggesting presence of carbohydrate 
moiety.   
At the end of Chapter 3, the 5% sodium hydroxide extract (fraction 4) from 
Paxillus obscurisporus was successfully purified using two different purification 
techniques that included size-exclusion chromatography and ion-exchange 
chromatography. The purified fractions obtained from two different purification steps 
were subjected to chemical characterization experiments like SDS-PAGE and total 
carbohydrate assay. The results confirmed the presence of carbohydrate and protein 
moieties. This information will allow to develop a purification strategy for further 
purification of anti-proliferative compounds from 5% sodium hydroxide extract (fraction 
4) of Paxillus obscurisporus. 
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Chapter 4 
General Discussion 
4.1  General project overview 
Between 1981-2002, 60% of new anti-cancer drugs were developed from sources of   
natural origin (Cragg & Newman, 2005). In the early 2000’s, the majority of 
pharmaceutical companies turned to newer synthetic small molecule libraries in search 
of novel anti-cancer agents, despite the success of natural products (Butler, 2008). This 
lack of interest in using natural products as a source of discovery of new medicine was 
due to several reasons.  It was recognized that purification and identification of 
medicinal compounds from natural products was a time-consuming process. The use of 
high-throughput screening (HTS) and increased speed of assays coupled with the ever 
increasing number of small molecule libraries as an alternative to natural product 
chemistry were a few reasons which attracted the interests of many pharmaceutical 
companies during the early 2000’s (Lam, 2007). However, in the last two decades, the 
lack of chemical diversity of synthetic small molecule libraries, disappointing results 
from the molecular libraries screened using HTS, recent advances in bioassays, and 
streamlined screening processes for natural products had rekindled the interest of  
pharmaceutical companies and other research groups towards natural products as a 
source of novel anti-cancer compounds (Eldridge et al., 2002; Ovadje et al., 2015).       
Mushrooms have been reported to possess bio-active anticancer molecules 
(Wasser, 2002). High molecular weight polysaccharides are best known to possess 
anti-tumor and immuno-modulatory activities. And lower molecular weight secondary 
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metabolites from mushrooms exhibiting antitumor activity (Ferreira et al., 2010). There 
is an abundance of mushroom species that are found in BC that have not been reported 
or studied for their anti-tumor activity. As seen in Table 1.3, BC is home to a wide range 
of biodiverse mushroom species that are yet to be studied for their potential anti-cancer 
properties.  
The primary goal of this study was to discover novel anti-cancer compound(s) from 
BC wild mushrooms. The specific aim of this study was to investigate various solvent 
extracts from five different British Columbian wild mushrooms for their potential anti-
proliferative and immuno-modulatory activity, and to purify and characterize an anti-
proliferative compound(s) from a selected mushroom extract. 
4.2  DNA identification of the collected mushrooms 
Upon collection of BC wild mushrooms, the samples were subjected to identification. 
The identification of species was performed by DNA sequencing analysis.  This was the 
first important endeavor because through proper identification of the mushroom species, 
the possibility of discovery of novel anti-cancer compound(s) was elevated by focusing 
on unstudied BC wild mushrooms. Through accurate identification, the focus was on 
mushroom species not reported to have any anti-cancer compound(s).  
The fungal DNA Internal Transcribed Spacer (ITS) region is known to exhibit 
variations in mushroom species (Kindermann et al., 1998; Martin & Rygiewicz, 2005). In 
this study, DNA sequencing of the ITS2 region of fungal DNA was used as a tool to 
identify mushroom species and was performed using ITS3 and NLB4 primers. DNA 
extracted and amplified from the five collected mushroom species were subjected to 
DNA sequencing. The results confirmed the identity of the five-mushroom species as 1) 
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Amanita muscaria, 2) Gyromitra esculenta, 3) Paxillus obscurisporus, 4) Phellinus 
igniarius, and 5) Trichaptum abietinum.  
Accurate identification of the BC mushroom species was an important step, as it 
helped to select the mushroom species that were not reported or studied for their anti-
cancer activity. Of the five mushroom species that were identified, Amanita muscaria 
and Phellinus igniarius were reported to possess anti-proliferative compounds. Amanita 
muscaria had been reported to possess bio-active anti-proliferative β-glucans from the 
alkaline extract (Kiho et al., 1992; Michelot & Melendez-Howell, 2003), and Phellinus 
igniarius had been reported to possess bio-active anti-proliferative endo-
polysaccharides from the hot water extract (L. Chen et al., 2011). Although, both 
Amanita muscaria and Phellinus igniarius were reported to possess anti-cancer 
properties, they were assessed for their anti-cancer properties in this study. This was 
because no reports/studies had been performed on the same mushroom species from 
BC. The selection was done on the belief that Amanita muscaria and Phellinus igniarius 
from BC may possess novel anti-cancer compound(s) as compared to the same 
species obtained elsewhere around the world because of their interaction with a 
different ecological setting in BC.   
By contrast, Gyromitra esculenta and Trichaptum abietinum were the mushroom 
species that are neither related to any of the bio-active species, nor had been reported 
to possess any bio-active compounds. Gyromitra esculenta is reported to possess a 
hydrazine derivative named N-methyl-N-formylhydrazine, known to be a carcinogenic 
agent (Toth & Nagel, 1978). Trichaptum abietinum is reported to be a wood decay 
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fungus (Kauserud & Schumacher, 2003). These two mushroom species are good 
candidates for future potential discovery of novel anti-cancer compounds.    
Finally, Paxillus obscurisporus was the mushroom that has not been reported to 
possess any bio-active compounds. However, it is related to mushrooms like Paxillus 
involutus and Paxillus panuoides, that have been reported to possess anti-proliferative, 
immuno-stimulatory and radical scavenging compound(s) (Ranta et al., 2013; Yun, et 
al., 2000).  
4.3  Assessment of biological activity of the BC wild mushrooms 
After the selected mushroom species were subjected to chemical extraction, the 
extracts obtained were subject to MTT assays and ELISA assays for assessment of 
anti-proliferative and immuno-stimulatory activities respectively.  
Our results indicated that the 85% ethanol extract from Amanita muscaria 
possessed strong anti-proliferative activity. Whereas, 5% sodium hydroxide (NaOH) 
extract from Amanita muscaria possessed mild immuno-stimulatory activity. This was an 
interesting finding as the 85% ethanol extracts from mushrooms are supposed to extract 
relatively small molecules (Mizuno, 1999) and Amanita muscaria is being reported to 
possess water insoluble β-glucans from the alkaline extract (Kiho et al., 1992; Michelot 
& Melendez-Howell, 2003). This suggests that the anti-proliferative compound(s) 
present in the 85% ethanol extract could be novel anti-cancer compound(s), as no low 
molecular weight compound had been reported from Amanita muscaria to possess anti-
proliferative activity. 
The 85% ethanol, 50% methanol, and hot water extracts from Gyromitra esculenta 
possessed strong immuno-stimulatory activity, but none of the extracts exhibited strong 
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anti-proliferative activity. Gyromitra esculenta had been reported to contain a hydrazine 
derivative toxin named “Gyromitrin”. No other bio-active compound had been reported 
from Gyromitra esculenta. So, the finding of immuno-stimulatory activity from the 
extracts is novel. 
The unstudied/unreported Paxillus obscurisporus showed potent anti-proliferative 
activity from 5% sodium hydroxide (NaOH) extract. Whereas, the 50% methanol, hot 
water, and 5% NaOH extract from Paxillus obscurisporus exhibited strong immuno-
stimulatory activity. This is an important finding since there is no bio-activity reported 
from any extract of Paxillus obscurisporus in the literature. 
The 50% methanol and hot water extract from Phellinus igniarius exhibited strong 
anti-proliferative activity. This was consistent with the reports earlier about extracellular 
endo-polysaccharides being reported from Phellinus igniarius. Strong immuno-
stimulatory activity was exhibited by 50% methanol extract, whereas mild anti-
proliferative activity was exhibited by 85% ethanol and hot water extract from 
Trichaptum abietinum. This was an important finding since no bio-activity has been 
reported from any extract from Trichaptum abietinum. 
The screening of various extracts from five mushroom species was an important 
endeavor. It offered the opportunity to confirm the reports about selected mushroom 
species like Amanita muscaria and Paxillus igniarius. It also offered the opportunity to 
discover anti-proliferative and immuno-stimulatory activity from unstudied/unreported 
mushroom species like Gyromitra esculenta, Paxillus obscurisporus, and Trichaptum 
abietinum. The knowledge of possession of anti-proliferative and immuno-stimulatory 
activity by certain extracts contributes to our goal in discovering novel natural anti-
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cancer compounds. These bio-active compounds found in this screening could be 
further purified and chemically characterized for identification of anti-cancer compounds. 
This screening helped to narrow down a more precise set of bio-active compound(s), 
that could be further purified and chemically characterized.  
4.4  Selection of Paxillus obscurisporus for purification of anti-proliferative 
compound(s) 
To potentially discover novel natural anti-cancer compound(s), a set of criteria and 
priorities was outlined that included: mushroom extract from an unreported/unstudied 
species; strong anti-proliferative or immuno-stimulatory or both activities exhibited by 
the bio-active fraction; the bio-active extract must be from mushrooms readily available 
in Prince George and the surrounding area; and the mushroom species could be related 
to other mushroom species reported to possess bio-active anti-cancer properties.  
Considering the above-outlined criteria, the 5% NaOH extract from Paxillus 
obscurisporus was selected for further purification and chemical characterization for this 
thesis. The 5% NaOH extract from Paxillus obscurisporus possessed moderate anti-
proliferative and strong immuno-stimulatory activities, which made it a favorable extract 
for further studies. Also, Paxillus obscurisporus is related to Paxillus involutus, which is 
reported to possess an anti-proliferative lectin with a molecular mass of 24 kDa against 
lung cancer cells (A-549) and human colon cancer cells (HCT-8) (Wang et al., 2013). 
Paxillus obscurisporus was collected by Drs. Keith Egger, Hugues Massicotte, and Zoë 
Meletis in different years from Prince George, which indicates that Paxillus 
obscurisporus is readily availability in Prince George and the surrounding area.    
91 
 
 
Although the extracts from Trichaptum abietinum and Gyromitra esculenta exhibited 
strong bio-activities, they were not selected for further purification. This was because it 
was very hard to collect Trichaptum abietinum as it visually resembles other mushroom 
species like Trichaptum biforme, Trametes versicolor, Trichaptum laricinum and several 
other polypores, therefore increasing the chances of cross contamination during 
identification through DNA sequencing. Whereas, the extracts from the Gyromitra 
esculenta were not selected for further purification because the fractions only had 
potent immuno-stimulatory activity and very mild anti-proliferative activity. Gyromitra 
esculenta has also been reported to possess potent carcinogenic hydrazine derivatives 
that are very toxic in nature (Toth & Nagel, 1978). The immuno-stimulatory activity could 
be the result of the hydrazine derivatives, although there have been no studies to 
determine that. The bio-active extracts from both Gyromitra esculenta and Trichaptum 
abietinum are worth pursuing however in future studies. 
As 5% NaOH extract from Paxillus obscurisporus was selected for further 
purification, it was important to reassess the bio-activity of the 5% NaOH extract from 
newly collected specimens of Paxillus obscurisporus. The DNA sequencing of the new 
specimens of Paxillus obscurisporus collected in 2015 revealed that its matched ITS2 
region of Paxillus obscurisporus genome by only 21%. Although there was ambiguity 
about proper identification of the mushroom, the specimens collected in 2015 retained 
its anti-proliferative and immuno-stimulatory activities. Despite the questionable identity, 
the Paxillus obscurisporus collected in 2015 was used for further analysis.  
 
92 
 
 
4.5  Purification of anti-proliferative compound(s) from Paxillus obscurisporus: 
Size-exclusion and anion-exchange chromatography 
 After 5% NaOH extract from Paxillus obscurisporus was selected for further 
purification and chemical characterization, it was initially subjected to size-exclusion 
chromatography. The Sephadex™ LH-20 size-exclusion medium separates the 
samples based on molecular size and has an operative range of 100 Da to 4000 Da, 
depending upon the shape of molecules. Since the 5% NaOH extract exhibited both 
anti-proliferative and immuno-stimulatory activities, it was expected that the 
Sephadex™ LH-20 would separate both the anti-proliferative and immuno-stimulatory 
compound(s) if they are not the same.  
Strong anti-proliferative activity was exhibited by fractions eluting out between 30%-
48% of total bed volume. This suggests that the compound(s) responsible for anti-
proliferative activity have a high molecular weight, possibly above 4000 Da. This is 
because part of the bio-active fractions are eluted before the exclusion limit. Exclusion 
limit is defined as the molecular weight at the upper end of the column 'working' range 
and is where molecules are too large to be trapped in the stationary phase.  
By contrast, the fractions containing immuno-stimulatory activity were eluted 
between 50%-90% of the total bed volume. This suggested that the fractions containing 
immuno-stimulatory activity were in the inclusion limit of the Sephadex™ LH-20, which 
is from 100-4000 Da. Since the immuno-stimulatory activity was exhibited by a series of 
fractions eluting from 50%-90%, it was considered that these compound(s) are in the 
inclusion limit. Compound(s) eluting out in these fractions could possibly range from 
high to low molecular weight (4000Da-1000Da or smaller). The results showed a clear 
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separation between the anti-proliferative and immuno-stimulatory compound(s) after the 
5% NaOH extract was subject to size-exclusion chromatography.  
Using size-exclusion chromatography was an important step for purification, as the 
anti-proliferative and immuno-stimulatory compounds could be separated using this 
technique. Since the focus was to purify the anti-proliferative fractions, the anti-
proliferative fractions obtained from the size-exclusion chromatography were pooled 
and their anti-proliferative activity was assessed in various cancer cell lines. It was 
observed that the post-Sephadex™ LH-20 fractions showed strong anti-proliferative 
activity at low concentration of 0.5 mg/mL. The time-dependent anti-proliferative activity 
of post-Sephadex™ LH-20 fractions revealed a pattern, where all the cell lines shows a 
spike in cell viability at the 24 hour time point. This suggests that the bio-active post-
Sephadex™ LH-20 fractions took 48 hours to exert their anti-proliferative activity in 
cells. This was only false for human papillary adenocarcinoma (H441) cells, which might 
be attributed to the slower growth rate of this cell line. 
After the size-exclusion chromatography, anion-exchange chromatography was 
performed as a second step for further purification of the anti-proliferative compound(s). 
The weak anion-exchange medium DEAE Sephadex™, which is positively charged, 
binds to any negatively charged compound(s) present in the sample that is passed 
through it. Several pH conditions were used with several buffers to determine the 
appropriate conditions for purification using the anion-exchange medium DEAE 
Sephadex™. A significant amount of time was spent to optimize the buffer, pH 
conditions and sample concentrations, which was suitable for purifying the bio-active 
compound(s) using DEAE Sephadex™. The search for optimized conditions led to the 
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conclusion that none of the conditions studied allowed the binding of the anti-
proliferative compound(s) to the DEAE Sephadex™. This suggested that the anti-
proliferative compound(s) are positively charged molecules that were not able to bind to 
DEAE Sephadex™.  
The most common procedure to use DEAE Sephadex™ as a purification step is to 
let the molecules of interest (anti-proliferative compounds) bind to the ion-exchanger 
and allow the others to pass through. However, since it was known that the anti-
proliferative compound(s) from Paxillus obscurisporus did not bind to the DEAE 
Sephadex™ in any given conditions, it was deemed more beneficial to bind the non-bio-
active contaminants to the DEAE Sephadex™ and let the molecules of interest remain 
in the flow-through. Piperazine 20 mM at pH 5.5 appeared to be the best buffer for this 
purpose, as the anti-proliferative activity was retained in the flow-through. Hence, 
piperazine 20 mM at pH 5.5 was used to perform anion-exchange chromatography to 
collect an ample amount of purified anti-proliferative compound(s) from Paxillus 
obscurisporus. The purified anti-proliferative compound(s) were further subjected to 
various assays for chemical characterization. The anion-exchange chromatography 
using DEAE Sephadex™ was an important second step for purification after size-
exclusion chromatography, as it ensured further purification of the anti-proliferative 
compounds.      
4.6  Assessment of the chemical nature of bio-active compound(s) from 
Paxillus obscurisporus 
By use of size-exclusion and anion-exchange chromatography, the purification of 
anti-proliferative compound(s) from 5% NaOH extract of Paxillus obscurisporus was 
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ensured firstly based on molecular size (size-exclusion), and then based on net ionic 
charge (anion-exchange) possessed by the molecule(s). To help understand the 
mechanism of action and to further purify the anti-proliferative compound(s) from 
Paxillus obscurisporus, it was very important to understand the chemical nature of the 
semi-purified anti-proliferative compound(s). To know more about the chemical nature 
of the anti-proliferative compound(s), it was firstly subjected to a carbohydrate assay. 
This was because majority of the pharmacologically active compound(s) reported to be 
found from mushroom species are polysaccharides (Ren et al., 2013; Zhang et al., 
2015). 
The post-Sephadex™ LH-20 fractions were subjected to the total carbohydrates 
assay and the results confirmed the presence of a polysaccharide moiety. It was 
observed that the concentration of carbohydrates was the highest in the fractions 
containing the anti-proliferative activity. Whereas, the concentration of the 
carbohydrates was lower in few fractions exhibiting immuno-stimulatory activity that 
were eluted just after the immuno-stimulatory fractions (please see Figure 3.12). This 
finding is critical for deciding the next step in performing the chemical characterization 
experiments on the purified anti-proliferative compound(s). 
Since the fungal polysaccharides are considered as macromolecules, the post-
DEAE Sephadex™ anti-proliferative compound(s) were subjected to SDS-PAGE 
technique, which separates the macromolecules on basis of their electrophoretic 
mobility. For assessing the presence of proteins, Coomassie blue was used as a stain 
and for glycoprotein a glycoprotein stain was used. Based on the SDS-PAGE staining 
experiments, the presence of protein and glycoprotein was confirmed. The presence of 
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a smear for both protein and glycoprotein in the sample suggested that the 
protein/glycoprotein are present in the anti-proliferative compound(s) from Paxillus 
obscurisporus. The smear may indicate the presence of a chained compound with 
fragments ranging from 10 kDa to 250 kDa for protein and from 35 kDa to 250 kDa for 
glycoprotein.  
Since there are several factors affecting the migration of the compound(s) while 
performing SDS-PAGE, a definitive conclusion cannot be drawn about the molecular 
weight of the anti-proliferative compound(s) from Paxillus obscurisporus. In summary, it 
can be concluded that the anti-proliferative compound(s) from 5% NaOH extract of 
Paxillus obscurisporus are positively charged molecules, which are likely to contain a 
mixture of chained proteins/glycoproteins with a varying range of molecular units.  
4.7  General overview and concluding remarks 
Mushroom extracts have historically been used as prophylactics and for treating 
several diseases (Israilides & Philippoussis, 2003). The medicinal compounds extracted 
from mushrooms could be divided into high molecular weight compounds and lower 
molecular weight organic compounds that are secondary metabolic products of various 
pathways (amino acid-derived pathways, the shikimic acid pathway for the biosynthesis 
of aromatic amino acids, and the acetate–malonate pathway from acetyl coenzyme A) 
(Zaidman et al., 2005). The fungal polysaccharides are one of the most potent 
mushroom derived bio-active macromolecules. For example, β-glucans from mushroom 
origins exhibit anti-cancer activity by stimulation of natural killer cells, T-cells, B-cells, 
macrophage-dependent immune system responses through distinct receptors. The 
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receptors it stimulates includes dectin-1, the toll-like receptor-2, scavenger receptors, 
apoptosis, and lactosylceramide (Brown & Gordon, 2005; Dalmo & Bøgwald, 2008).  
In this study, several extracts obtained from five BC wild mushroom species were 
found to be either immuno-stimulatory or anti-proliferative or both. This was an 
important finding as bio-active fractions from mushroom species like Gyromitra 
esculenta, Paxillus obscurisporus, and Trichaptum abietinum were found to be sources 
of potential novel anti-cancer compounds. Although Amanita muscaria has been 
reported to have β-glucans possessing anti-proliferative activity, the anti-proliferative 
activity shown by 85% ethanol extract was an interesting finding. This was because the 
β-glucans are water insoluble polysaccharides that are reported to be extracted in 5% 
NaOH (Michelot & Melendez-Howell, 2003; Mizuno, 1999). So, further purification of the 
ethanol extract suggests the possible discovery of potential small molecule anti-cancer 
compound(s).  
The strong anti-proliferative activity exhibited by the post-Sephadex™ LH-20 
fractions of Paxillus obscurisporus, was one of the important findings. This was because 
the anti-proliferative activity shown by 0.5 mg/mL post-Sephadex™ LH-20 fractions was 
found to be more potent than the 1 mg/mL crude 5% NaOH extract from Paxillus 
obscurisporus. This was an indication that the purification using size-exclusion 
chromatography was a successful and useful purification step. The optimization of 
various buffers and pH conditions revealed that none of the buffer and pH conditions 
that were tested was successful to bind the ™LH-20 fractions to DEAE Sephadex™. 
This was an important finding as it helped to conclude that the post-DEAE Sephadex™ 
anti-proliferative compounds from Paxillus obscurisporus might possess a positive net 
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surface charge. Another important finding from this study includes the determination of 
the presence of carbohydrate and protein moieties in the fractions obtained from the 
size-exclusion and anion-exchange chromatography of 5% NaOH extract from Paxillus 
obscurisporus. This was an important finding as it will help to select various techniques 
to further purify chemically and biochemically characterize the bio-active compound(s) 
in future studies. 
Although the 5% NaOH extract from Paxillus obscurisporus was purified using size-
exclusion and anion-exchange chromatography, further purification and characterization 
is needed. As deduced from the results of anion-exchange chromatography, the anti-
proliferative compound(s) obtained from the 5% NaOH extract of Paxillus obscurisporus 
seemed to have a net positive surface charge. This conclusion helps to select cation-
exchange chromatography as a possible future purification technique. The benefit of 
this mode of purification may involve binding of the active anti-proliferative compound(s) 
to the cation-exchange medium to permit further purification.     
The chemical characterization of post-DEAE Sephadex™ flow through, confirmed 
the presence of proteins and carbohydrate moieties. Common methods used in 
purification and characterization of fungal polysaccharides or glycoproteins include Gas 
Chromatography/High Performance Liquid Chromatography, Nuclear Magnetic 
Resonance and Infrared Chromatography analysis of the hydrolyzed fungal extracts 
(Kiho et al., 1993; Sun et al, 2004; Zhang et al., 2015). If a polysaccharide or 
glycoprotein is the compound(s) responsible for the anti-proliferative activity, these 
analytical methods would provide useful information as to the types of sugar moieties 
the polysaccharides are constituted of, type of linkages between them, etc.  
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Lastly, it is of prime importance to understand the molecular mechanism through 
which the anti-proliferative activity is being exhibited by compound(s) from 5% NaOH 
extract of Paxillus obscurisporus. In order to understand this, the expression of various 
apoptosis-related proteins like Bcl-2, Bcl-3, Bax, and procaspase-3 in the cell lines 
could be performed by Western blot analysis (Oh et al., 2008).       
Overall, this study serves as a significant platform for future investigations into 
discovering novel anti-cancer compounds from BC wild mushrooms. The novel bio-
active extracts from mushrooms species like Gyromitra esculenta, Paxillus 
obscurisporus, and Trichaptum abietinum serve as potential sources for the discovery of 
novel anti-cancer compounds. With the successful purification of anti-proliferative 
compound(s) from Paxillus obscurisporus using size-exclusion and anion-exchange 
chromatography, and the confirmation that it contains proteins and carbohydrates, 
future experiments can now be logically planned to further purify the compound(s) and 
to further understand its mechanism of action and its chemical composition.  
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Appendix 
(i) Amanita muscaria  
ITS3: 
NNNNNNNNNNNTGCANANTCNGTGNTCNTCGAATCTTTGACNCNTCTTGCGCTCCTTG
GTATTCCNAGGANCATGCCTGTTTGAGTGTCATTAAATTCTCTCAAAGCATACACTTGA
GTGTGTGTTTTGGATTGTGGGAGTGTCTGCTGGCTTTATTATNANCCNNNTCTCCTGAA
NNANATTNNNTTTGGGGNGGAGGTGCCNAGTNNCTTCTGCCTTTCNNTTGNNGTGATA
GATGAATTANCTTATCTACNCNANGANANNNNGCTGNNGGTGATGCNCTGTGATCTCT
CTCTGCTCTCTANTTGACNTTTGNNTGATANCTTGACCTCNNATCNNGNANGACTACCC
GNTGAACTTNANCNTATCAATANNNGGANGAAAANAAACTAACNANGATTCCCTTANNN
NCTGCNANTGAAGANGGAANANCTCNNATTTANNATCTGGNGNTGTTTTGCNGNNNNA
GTTGTNNTCTANAGAANTGCTGCCCGTGCTGNACCNTGTACNANTCTCNNGNANNGGA
NCGTNNNNNNNNNNNANNNNANNAANNNNGGNNNNNNNANNNNGGNNNGNNNNNNN
NGGCNNNNNNNNNCTAAANNNNNNTCNGANANNNNNCNCNGACNNNNTTTAANNNNN
NNNCTNCCNNNNNNNCTAGNNNNNANNNAANCNTNNNNANTTTNCNNNNCNCNCTTAN
TNNNANNNNTANNNNNCNNNNACNNNNNTNNANTNNNNNNNNNNTANCNNNANNNNN
NNNNTANNNNNAANNNAANNCNNNNCNTCCCNNNNNNNNNNNTNNNNNNNNNAATTAN
TTTNNTTNNNNNNNNNNNNGGNNANGANNNANNNNNNNNNNCCCNNNNNNGNNNNNN
NNTNTNNNGNNNGNGNNGNNNNNNNNNNAAANNNNNNNNNNNNCNNNNNCNNNNNN
NNN 
NLB4: 
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNCTTNTCTAGATTACNACT
CGGACAGCNAAACACTGCCNNATTTNNAATTTGAGCTCTTCCCTCTTCACTCGCAGTTA
CTAAGGGAATCCTTGTTAGTTTCTTTTCCTCCGCTTATTGATATGCTTAANTTCAGCGGG
TAGTCCTACCTGATTTGAGGTCAAGTTATCAGACAAATGTCAATTANAGAGCAGAGAGA
GATCACAGTGCATCACCTGCAGCCTGCTTTCCTGGCGTANATAANTTAATTCATCTATC
ACACCAATGGAAAGGCANAAGTGACTTGGCACCTCCCCCCCAAAGCTAATGTCNTTCA
NGAGAGCTGGCTCATAATANNANCAGANNNNACTCCCNNNNNNNANAANANNNNCTCN
NNNNNNTGCNNNNNNANAAATTGANGANNCTCNNNNNNNNNTGCTCNTCNNANTACCN
ANGANCNNANGATGNNNNNNANNANACNATGNNNCNNTGNCNNCNNNNNNTCNNANN
NNNNANNNNANNNCNCANNNNCNTCNNCNNNNNN 
 
(ii) Gyromitra esculenta 
ITS3: 
GNNNNNNNNNTGTNANGCAGATTCNGTGNTCATCGAATCTTTGAACGCACATTGCGCC
CTCTGGCATTCCGGAGGGCATGCCTGTTCGAGCCTCAATGAAACCGCTCCCCTCCTGG
CGCTTCTCGGAGCAAAACGGCGGGGGTTCTGGCGGACGCGAACGCCGTCAATGGCTT
CTTGCGCCGCTCAAATCGACGGTCTGCAGGCCCCGAGGGCGCACCCGACGTAGTGAT
AACATTTCTCGTCGACGGCGACCCCGGTGCTCCTGAGACCCTAAGCGTTTCGGCGCCA
AACCCAATCGGTTGAGCTCGGATCAGGTAGGGATACCCGCTGAACTTAAGCATATCAA
TAAGCGGAGGAAAAGAAACCAACAGGGATTGCCTCAGTAACGGCGAGTGAAGCGGCA
ACAGCTCAAATTTTAAAGCTGACGTCTTTGGCGTCCGCGTTGTAATTTGGAGAGGCATC
TTCGGTTTGGGCGCCAGCCTATGTTCCTTGGAACAGGACGTCATAAGGGGGNNAAAAN
CNAAA 
xxv 
 
 
 
NLB4: 
NNNNNNNNNANGCTGGCNNANCCGAAGANGCCTCTCCNANTTACAACGCGGACGCCA
AAGACGTCAGCTTTAAAATTTGAGCTGTTGCCGCTTCACTCGCCGTTACTGAGGCAATC
CCTGTTGGTTTCTTTTCCTCCGCTTATTGATATGCTTAAGTTCAGCGGGTATCCCTACCT
GATCCGAGCTCAACCGATTGGGTTTGGCGCCGAAACGCTTAGGGTCTCAGGAGCACC
GGGGTCGCCGTCGACGAGAAATGTTATCACTACGTCGGGTGCGCCCTCGGGGCCTGC
AGACCGTCGATTTGAGCGGCGCAAGAAGCCATTGACGGCGTTCGCGTCCGCCAGAAC
CCCCGCCGTTTTGCTCCGAGAAGCGCCAGGAGGGGAGCGGTTTCATTGAGGCTCGAA
CAGGCATGCCCTCCGGAATGCCAGAGGGCGCAATGTGCGTTCAAAGATTCGATGATTC
ACTGAATTCTGCAATTCACATTACTTATCGCATTTCGCTGCGTNNNNNNNCNANNNA 
 
(iii) Paxillus obscurisporus (2013) 
 
ITS3: 
NNNNNNNNNNNNNNGNNNTNNNGTNNNCNNCNNTCTTTGNNCGCACCTTGCGCTCCT
TGGTATTCCGAGGAGCATGNCTGNTTGAGTGTCATTTAATTCTCAACCATCCCTCGATT
CGTTTCGAGGTTTGGCTTGGATTTTGGGGGCTGCCGGGCGACCCTAGGGTCTTCGGC
TCTCCTTAAAAGCATTAGCGATGGTGGAACGACCTAACNCCATGCATGAACGGCCTTC
GACGTGATAATGATCGTCGTGGCTGGAGTGCTAGCGGGCGTCGTGAAATNGGCGCTT
CTAAATCTCGTCNAAAGACGAAACTCGAAACTTGACCTCAAATCANGTAGGACTACCCG
CTGAACTTANGCATATCAATAAGCGGAGGAAAAGAAACTAACAAGGATTCCCCTANTAA
CTGCGAGTGAANCGGGATGAGCTCAAATTTTGAATCTGGNGGTCTTCANGCCGTCCGA
NTTGNAATCTANAGAANCGTCTTCCNCNCTGGANNNNGTNNAANTCTCCNGGAANGNN
NCGTCNNNNNGGNGNNNAANNN 
 
NLB4: 
NNNNNNNNNNNNNNNNNNNNNNNNNNNGNNNNNGCTTCTCTAGATTACAACTCGGAC
GGCCTGAAGACCGCCAGATTCAAAATTTGAGCTCATCCCGCTTCACTCGCAGTTACTAG
GGGAATCCTTGTTAGTTTCTTTTCCTCCGCTTATTGATATGCTTAAGTTCAGCGGGTAGT
CCTACCTGATTTGAGGTCAAGTTTCGAGTTTCGTCTTTCGACGAGATTTAGAAGCGCCN
ATTTCACGACGCCCGCTAGCACTCCAGCCACGACGATCATTATCACGTCGAAGGCCGT
TCATGCATGGNGTTAGGTCGTTCCACCATCGCTAATGCTTTTAAGGAGAGCCGAANAC
CCTAGGGTCGCCCGGCAGCCCCCAAAATCCAAGCCAAACCTCGAAACGAATCGAGGG
ATGGTTGAGAATTAAATGACACTCAAACAGGCATGCTCCTCGGAATACCAAGGAGCGC
AAGGNGCGTTCNAANATTCNATGANTCACTGNAAATCTGCAATTCACATTNNTTATCGN
AATTCNCNNNNNNNTNNNTCNA 
 
(iv) Paxillus obscurisporus (2015) 
 
ITS3: 
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNTGNNCNTCNNNTCTTTGAACGCACC
TTGCGCTCCTTGGTATTCCGAGGAGCATGCCTGTNNGAGTGTCATTTAATTCTCAACCA
TCCCTCGATTCGTTTCGAGGTTTGGCTTGGANTTTGGGGGCTGCCGGGNNNCCNNNG
GGCNTNNGNNNNNCNTNNAANNNNTNANNNNGGGGGNANNNNCNNANCNNNNTGGA
NNAGNCNNCNNCNNNNTNATGATNNTCNNGGCGGGNGNGNTGNNNGGNGNCGTGAA
GNCANCGCTTCTTCATCNTCNNCNANAAANAANACTTTNAAACTTGNNCNCNNANCNNG
GNNNNNNNCCCNNNNNANNTNANNNNNNTNANNANNNGNNGAAAANAAANNNNNNAN
NNNNCCCCNNNNNANNNNNNNNNNANCNGGNNNNNNNCNNATTTTNNNTNNNGNNGN
xxvi 
 
 
NCTNNNGNCNNCCNAANTNNNATCCNNNNNANNNNCCTNCNNNNNNNANNNNGNNNN
ANNNNNCNNNNANNNNNNNNCNNNNNNNGNGA 
 
(v) Phellinus igniarius 
 
ITS3: 
CATCGAATCTTTGAACGCACCTTGCGCCCCTTGGTATTCCGAGGGGCATGCCTGTTTG
AGTGTCATGTTAATTTCAACTCCCCTTGTTTCTTAACTCGGGTGTGTTGGACTTGGAAG
CTGCTGGCCCCCTTCGTTGTGGTCGGCTCTTCTTAAATGCATTAGCTGGGCTTTGGCTC
GCGCTGAACGGTGTAATAGTAATCTTACATTCACCTGAGCGCTTGCCTAACAAGTCTGC
TTCTAATCGTCCGTGTTTTCGGACAAGGTCGCTTTGTCGCCTTCATTTGACACCTTGAC
CTCAAATCAGGTAGGATTACCCGCTGAACTTAAGCATATCAATAAGCGGAGGAAAAGAA
ACTAACAAGGATTCCCCTAGTAACTGCGAGTGAAGAGGGAAAAGCTCAAATTTAAAATC
TGGCGGGCTCTGCTCGTCCGAGTTGTAATCTGGAGAAGCGTTTTCCGCGTCGGACCGT
GCATAAGTCTCCTGGAACGGAGCGTCATAG 
 
NLB4: 
GAACGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCT
TTGAACGCACCTTGCGCCCCTTGGTATTCCGAGGGGCATGCCTGTTTGAGTGTCATGT
TAATTTCAACTCCCCTTGTTTCTTAACTCGGGTGTGTTGGACTTGGAAGCTGCTGGCCC
CCTTCGTTGTGGTCGGCTCTTCTTAAATGCATTAGCTGGGCTTTGGCTCGCGCTGAAC
GGTGTAATAGTAATCTTACATTCACCTGAGCGCTTGCCTAACAAGTCTGCTTCTAATCGT
CCGTGTTTTCGGACAAGGTCGCTTTGTCGCCTTCATTTGACACCTTGACCTCAAATCAG
GTAGGATTACCCGCTGAACTTAAGCATATCAATAAGCGGAGGAAAAGAAACTAACAAGG
ATTCCCCTAGTAACTGCGAGTGAAGAGGGAAAAGCTCAAATTTAAAATCTGGCGGGCT
CTGCTCGTCCGAGTTGTAATCTGGAGAAGCGTTTTCCGCGTCGGACCGTGCATAAGTC
TCCTGGAACGGAGCGTCATAG 
 
(vi) Trichaptum abietinum 
 
ITS3: 
NNNNNNNNNNNGCNNANTCNGTGNNCNTCGNNTCTTTGACGCACCTTGCGCTCCTTG
GTATTCCGAGGAGCATGCCTGTTTGAGTGTCATGTTAATATCAACCCCGTCGGTTTGTN
AATCNNACCGTTGGGTGTTGGACTTGGAGGTTCTTGCTGGCTGCAAAGTCGGCTCCTC
TTGAATGNATTAGCTTGGGCCTGTTGTNCGTGCTCGCGGTGTAATAAGTTTTATTCATC
GTTTGGGTCGTACACTTATTGGGCTTGCTTCTAACTGTCTTCGGACAAANATAACCTTT
GACTCTGACCTCAAATCAGGTAGGACTACCCGCTGAACTTAAGCATATCAATAAGCGGA
GGAAAAGAAACTAACAAGGATTCCCCTAGTAACTGCGAGTGAAGCGGGAAAAGCTCAA
ATTTAAAATCTGNCGGTTTCACCGTCCGAGTTGTAATCTGGAGAAGCGTTTTCCGTGTC
GGACCGTGNACAAGTCTCTTGNAACAGANCGTCNTANNNNNNNNNNAA 
 
NLB4: 
NNNNNNNNNNNNNNNNNNNGGNNNNGCTTCTCCNGATTACAACTCGGACGGTGNAAC
CGNCAGATTTTAAATTTGAGCTTTTCCCGCTTCACTCGCAGTTACTAGGGGAATCCTTG
TTAGTTTCTTTTCCTCCGCTTATTGNTATGNTTAAGTTCAGCGGGTAGTCCTACCTGATT
TGAGGTCAGAGTCAAAGGTTATNTTTGTCCGAAGACAGTTAGAAGCAAGCCCAATAAGT
GTACGACCCAAACGATGAATAAAACTTATTACACCGCGAGCACGNACAACAGGCCCAA
GCTAATNCATTCAAGAGGAGCCGACTTTGCAGCCAGCAAGAACCTCCAAGTCCAACAC
CCAACGGTNNGATTNACAAACCGACGGGGTTGATATTAACATGACACTCAAACAGGCA
TGCTCCTCGGAATACCNAGGANCGCAAGGTGCGTTCAAAGANTCNANGANTCACTGAA
xxvii 
 
 
NTCTGCNANTCACATTACNTATCGCATTTCGCTGCNNNNNNNNNNNNNNNNNNNNNNG
NNNNNNNNNNA 
 
(vii) Calculations model for dose and time-dependent MTT assay: 
 
Dose-dependent MTT Assay: 
 
% Cell Viability = [(Absorbance of control)/(Absorbance of samples)] X 100 
 
Time-dependent MTT Assay: 
 
A) For Samples 
% Cell Viability = [(Absorbance of samples)/(Absorbance of control at day 6)] X 100  
 
B) For Control 
% Cell Viability = [(Absorbance of control)/(Absorbance of control at day 6)] X 100  
 
 
 
 
 
 
 
 
